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γ-aminobutyric acid type A receptors (GABAA receptors) underlie the majority of inhibitory 
synaptic transmission in the brain. Modulation of GABAergic activity occurs in development 
and normal physiological functioning of the brain, and changes to GABAergic function has 
been implicated in numerous neurological disorders including epilepsy. Neurosteroids, 
metabolites of steroid hormones, and kinases are known to modulate GABAA receptor 
mediated currents in health and disease. This thesis aims to investigate the effects of kinases 
and neurosteroids on modulating GABAA receptor-mediated currents in cortical pyramidal 
cells and their effects on the piriform cortex (PCtx) circuit in naïve rats and in rats after kindling 
(animal model of epilepsy). Specifically, we investigated:  
1) The effects of kinase activators on neurosteroid-induced modulation of GABAA 
receptor mediated currents, using inhibitory neurosteroid tetrahydrodeoxy-
corticosterone (THDOC) and excitatory neurosteroid pregnenolone sulfate (PregS). 
2) The effect of neurosteroid THDOC and protein kinase modulation on the PCtx circuit  
3) The effect of THDOC and kinase modulation in the PCtx after kindling  
We found that kinases differentially modulate the potentiating effect of THDOC on phasic and 
tonic inhibition, where they suppressed enhancement of tonic inhibition, but had no effect on 
phasic inhibitory postsynaptic currents (IPSCs). By contrast, kinases did not modulate the 
effect of excitatory neurosteroid PregS on phasic and tonic inhibition. In the PCtx circuit, 
THDOC suppressed the activity of the circuit, and this effect was blocked by prior kinase 
activation. After kindling, we found that THDOC no longer suppressed the circuit activity. 
Protein kinase C activation partially restored the effect of THDOC after kindling. Our findings 
show that protein kinase activities regulate neurosteroid-mediated modulation of GABAergic 
inhibition and that regulation of protein kinase activity may be able to restore normal 
neurosteroid functioning in epilepsy. 
Keywords: neurosteroid, THDOC, pregnenolone sulfate, protein kinase, PKA, PKC, 




Summary for Lay Audience 
The brain is a complex organ that controls our body and mental function. It consists of neurons 
that form intricate networks. These neurons communicate through excitatory and inhibitory 
electrochemical signals. The balance between excitation and inhibition in the brain is crucial 
for normal function of the brain, and disturbances to the balance is implicated in brain disorders 
such as epilepsy.   
γ-aminobutyric acid type A receptors (GABAA receptors) are responsible for inhibition of the 
brain. Their activities can be altered by many molecules, including those made in the body. In 
this thesis, we investigated two classes of such molecules: neurosteroids and protein kinases. 
Neurosteroids are made from hormones in our body, and they can alter the function of GABAA 
receptors. The neurosteroid tetrahydrodeoxycorticosterone (THDOC) enhances GABAA 
receptor function and thus enhances inhibition of the brain. Protein kinases can also alter the 
function of GABAA receptors, but they can also alter the effect of neurosteroids on GABAA 
receptors. The main goal of this thesis was to investigate how neurosteroids and protein kinases 
alter GABAA receptor function at cellular level (in single neuron) and at network level (in 
network of neurons), specifically in the piriform cortex, a region of the brain known to be 
extremely susceptible to seizures, and how the effects of neurosteroids and protein kinases 
change in epilepsy, using an animal model.  
We found that the effect of THDOC on GABAA receptors is decreased when protein kinases 
were applied at cellular level. Similarly, in the piriform cortex circuit, protein kinases blocked 
the inhibitory effect of THDOC. In the piriform cortex of epileptic brain, however, we found 
that THDOC no longer enhanced the inhibition by GABAA receptors. When the epileptic brain 
was treated with protein kinases, the effect of THDOC was restored, and THDOC was able to 
enhance GABAA receptor function and thus inhibition of the brain. Our findings show that 
changing protein kinase activities may be able to restore normal functioning of neurosteroids 
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Chapter 1  
1 Introduction 
 General Introduction 
The brain is a complex organ that controls physical and mental functions, from heart rate 
to complex cognitive functions. Neurons, the smallest functioning units of the brain, form 
highly organized interconnected networks. They communicate with each other via 
electrochemical signals that can be excitatory or inhibitory. The balance between excitation 
and inhibition (E/I balance) is critical in normal brain function, and disturbances to the 
balance has been linked to numerous neurological and psychiatric disorders such as autism, 
schizophrenia, and epilepsy (Rubenstein and Merzenich, 2003; Fritschy, 2008; Kehrer et 
al., 2008). 
γ-aminobutyric acid type A receptors (GABAA receptors) are the main mediator of 
inhibition in the brain. They are modulated by various endogenous molecules such as 
neurosteroids and kinases. Modulation of GABAergic activity occurs in development and 
normal physiological functioning of the brain (Brussaard et al., 1997; Hutcheon et al., 
2000; Koksma et al., 2003), and changes to GABAergic function or its modulation has 
been implicated in epilepsy, a disorder characterized by recurrent seizures of excessive 
hypersynchronous neural activities (Schwabe et al., 2005; Gavrilovici et al., 2006; Kia et 
al., 2011). Thus, information about how GABAA receptor is modulated is essential in 
understanding both the physiology of the brain and pathophysiology of epilepsy.   
This thesis aims to investigate the effects of kinases and neurosteroids on modulating 
GABAA receptor-mediated currents in cortical pyramidal cells and their effects on the 
piriform cortex (PCtx) circuit, a highly seizure-susceptible region of the brain.   
 GABA 
GABA is the main inhibitory neurotransmitter in the central nervous system (CNS). It is 
typically synthesized from glutamate by glutamate decarboxylase (GAD) (Olsen & 
DeLorey, 1999). GABA binds and activates two classes of receptors: GABAA receptors 
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and GABAB receptors. GABAA receptors are ionotropic receptors and GABAB receptors 
are metabotropic G protein-coupled receptors (GPCRs). This thesis will focus on GABAA 
receptors.  
 GABAA receptor structure & function 
GABAA receptor, a ligand-gated ion channel, mediates inhibition in the brain. Binding of 
two GABA molecules results in opening of the channel, typically resulting in influx of Cl−, 
hyperpolarizing the cell. Binding of GABA increases the probability of the receptor 
channel opening, and the channel opens and closes rapidly, creating bursts of Cl− flow 
(Macdonald & Twyman, 1991). Low concentration (< 2 μM) of GABA results in short/low 
frequency channel openings, whereas higher concentration results in longer open duration 
and higher burst frequency (Macdonald & Twyman, 1991). Action potentials from 
presynaptic neuron and ensuing vesicular release will cause phasic increase of GABA 
concentration (1.5–3.0 mM) in the synaptic cleft (Tretter & Moss, 2008). As GABA is 
cleared away from the synaptic cleft (via diffusion and GABA reuptake by GABA 
transporters), the receptor will deactivate as GABA unbinds and the channels close. 
Increasing the burst duration/frequency or prolonging deactivation of the receptor can 
enhance GABAergic currents.  
Normally in mature neurons, opening of GABAA receptor near the resting membrane 
potential (e.g. −60 mV) results in influx of Cl− due to the electrochemical gradient. The 
equilibrium potential for Cl− is typically slightly below the resting membrane potential, so 
the high extracellular [Cl−] causes influx of Cl−. However, Cl− can flow out of the cell if 
intracellular [Cl−] increases and the Cl− equilibrium potential depolarizes, making 
GABAergic transmission excitatory. This depolarizing GABAergic current is seen during 
early development due to the lack of K+/Cl− cotransporter type 2 (KCC2) (Rivera et al., 
1999; Ben-Ari, 2002). GABAA receptor also has some permeability to bicarbonate ion 
(HCO3−) with HCO3− vs. Cl− permeability ratio of 0.2 (Kaila et al., 1993). While Cl− 
typically flows into the cell, HCO3− typically flows out of the cell. 
GABAA receptors are heteropentamers made up from a combination of 19 different 
subunits: α(1-6), β(1-3), γ(1-3), δ, ε, θ, π, and ρ(1-3) (Olsen & Sieghart, 2009; Stefanits et al., 
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2018). Typical synaptic receptors contain two α, two β, and one γ subunits, with the most 
common combination being α1β2γ2 which accounts for ~60% of all GABAA receptors, 
followed by α2βxγ2 (where x = 1, 2, or 3) (McKernan & Whiting, 1996; Whiting et al., 
1999; Carver & Reddy, 2013). Each subunit consists of one extracellular domain at the N-
terminus, four transmembrane domain, and one intracellular loop that links M3 and M4 
transmembrane domain (Figure 1.1) (Chuang & Reddy, 2018). GABA binding sites are 
located between α and β subunits.  
Approximately 90% of all GABAA receptors contain γ subunit (Sieghart, 2006). These 
synaptic receptors mediate phasic inhibition known as inhibitory postsynaptic currents 
(IPSCs). IPSCs are synchronous opening of GABAA receptors in response to presynaptic 
release of GABA vesicle(s). At a single synapse, it is estimated that tens or hundreds of 
GABAA receptors are present (Nusser et al., 1997; Nusser, 1999). IPSCs can regulate 
neuronal excitability and can control cell firing and network rhythmicity in the CNS with 
temporal specificity (Fritschy, 2008).  
There are several “types” of IPSCs that are experimentally measured and can inform 
specific properties of GABAergic synaptic transmission. Spontaneous IPSCs (sIPSCs) are 
IPSCs resulting from spontaneous release of GABA vesicles resulting from spontaneous 
action potential firing of presynaptic neurons as well as action potential-independent 
vesicular release. They are typically recorded in the presence of glutamatergic receptor 
antagonists. Miniature IPSCs (mIPSCs) are IPSC resulting from release of GABA vesicles 
in the absence of presynaptic action potentials. These events are recorded with voltage-
gated Na+ channel blocker tetrodotoxin (TTX) to block action potentials.  Miniature events 
were first described by Fatt and Katz (1952) when they recorded responses from 
postsynaptic muscle cell in response to acetylcholine. Such events occur with other 
neurotransmitters like GABA and glutamate, and they are thought to represent the 
postsynaptic action of a single synaptic vesicle of neurotransmitters (Fatt and Katz 1952; 
Ropert et al., 1990). Evoked IPSCs (eIPSCs) are IPSCs that are artificially generated, 
typically by stimulation of presynaptic cells and/or their afferent axons. Focal application 
of saturating concentrations (mM range) of GABA can also be used to mimic a presynaptic 
GABA release.  
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The most obvious function of phasic GABAA receptor-mediated inhibition (IPSCs) is to 
prevent overexcitation of neurons that may lead to excitotoxicity or aberrant neuronal firing 
seen in neurological diseases such as epilepsy and schizophrenia (Roberts, 1972; Esclapez 
& Trottier, 1989; Olsen et al., 1992; Treiman, 2001; Sperk et al., 2009; Hunt et al., 2017). 
Phasic inhibition is also responsible for generating rhythmic network activities. A typical 
IPSC is initiated by release of GABA from the presynaptic axon terminals into the synaptic 
cleft causing a peak concentration of 1.5–3 mM (Tretter & Moss, 2008). As GABA 
concentration decays in the synaptic cleft, IPSCs typically decay in 2 phases: fast decay 
with decay time constant (τ) ranging from a few to tens of milliseconds, followed by slow 
decay, with τ in the range of tens or hundreds of milliseconds (Jones & Westbrook, 1995; 
Dominguez-Perrot et al., 1996; Kia et al., 2011). 
There also exist GABAA receptors in the extrasynaptic and perisynaptic membrane. They 
typically contain δ subunit, with two α and β subunits. These extrasynaptic receptors have 
high affinity to GABA and are activated by low ambient concentration of GABA 
(estimated to be in low μM range) in the extrasynaptic space (Tossman et al., 1986; Wei et 
al., 2003; Kuntz et al., 2004; Farrant & Nusser, 2005; Roth & Draguhn, 2012). The 
persistent conductance produced by extrasynaptic receptors are termed tonic inhibition. 
Tonic inhibition controls the overall excitability of the cell as it can diminish the size and 
duration of excitatory currents and make action potential generation less likely (Farrant & 
Nusser, 2005). Depending on brain region, tonic inhibition can account for ~80% of 
GABAA receptor conductance (Nusser & Mody, 2002; Farrant & Nusser, 2005; Belelli et 
al., 2005). Changes to tonic inhibition or δ subunit expression can affect network oscillation 
and are often associated with neurological disorders (Peng et al., 2004; Mann & Mody, 











Figure 1.1 Schematic diagram of GABAA receptor subunit structure 
GABAA receptor subunit has one extracellular domain, four transmembrane domain (TM) 
and one intracellular loop between TM3 and TM4. The intracellular loop contains 
phosphorylation sites.  
Reprinted from “Genetic and molecular regulation of extrasynaptic GABA-A receptors in 
the brain: therapeutic insights for epilepsy” by S. Chuang and D. S. Reddy 2018. The 
Journal of Pharmacology and Experimental Therapeutics. Copyright © 2018 The 





 GABAA receptor desensitization 
GABAA receptors are known to desensitize when exposed to its ligand GABA. GABAA 
receptor desensitization occurs when the receptor closes while still bound to GABA. The 
desensitization of neurotransmitter-gated ion channels like GABAA receptor is different 
from that of GPCRs as it is fast, and the receptors do not internalize. Altering 
desensitization affects the kinetics of IPSCs (Dominguez-Perrot et al., 1996; Jones & 
Westbrook, 1996).  
Somewhat counterintuitively, desensitization plays a key role in prolonging GABAergic 
IPSCs. GABA, after being released into the synaptic cleft, is cleared away within a few 
milliseconds (Cupello & Hydén, 1986; Clements, 1996). Yet, IPSCs typically last much 
longer, with decay time constants of tens or hundreds of milliseconds (Jones & Westbrook, 
1995; Hutcheon et al., 2000; Ing & Poulter, 2007; Kia et al., 2011). This is due to receptors 
entering desensitization state. GABAA receptors, when activated by brief pulse of GABA 
like that seen in IPSC, oscillate between open and closed (desensitized) state (40-70 ms) 
until GABA molecules unbind. Hence, receptors that enter long desensitization states 
remain bound to GABA for longer periods and can open even after GABA has been cleared 
away from the synaptic cleft. As GABA remains bound for longer, this results in longer 
deactivation (unbinding and closing of the receptor channel) of the receptor and thus 
enhanced IPSCs.  
There are two different desensitized states: fast and slow (Figure 1.2 and 1.3) (Jones & 
Westbrook, 1995; Dominguez-Perrot et al., 1996). The fast desensitized state has high 
entry and exit rate with short dwell time, and the slow desensitized state has slower entry 
and exit rates with longer dwell time. The biexponential decay of IPSCs is thought to be 
due to the two different desensitization states (Jones & Westbrook, 1995; Dominguez-
Perrot et al., 1996). It is suggested that the initial fast decay component of IPSC is shaped 
by fast desensitization and the latter slow decay component is primarily shaped by 
receptors reopening after exit from slow desensitization (Jones & Westbrook, 1995; 









The model by Jones and Westbrook shows that GABAA receptor bound to single GABA 
molecule can enter slow desensitized state (Dslow), and receptor bound to two GABA 
molecules can enter fast desensitized state (Dfast).  
Reprinted from “Desensitized states prolong GABAA channel responses to brief agonist 
pulses” by M. V. Jones and G. L. Westbrook 1995. Neuron 15:181-191. Copyright © 1995 
Cell Press. Reprinted with permission.  









The model by Dominguez-Perrot, Feltz, and Poulter show that GABAA receptor (R) bound 
to two GABA molecule (A) can enter slow desensitized state before opening (ARAds), and 
after opening (ARAopen), it can enter fast desensitized state (ARAdf).  
Reprinted from “Recombinant GABAA receptor desensitization: the role of the γ2 subunit 
and its physiological significance” by C. Dominguez-Perrot, P Feltz, and M. O. Poulter 
1996. Journal of Physiology 497.1:145-159. Copyright © 1996 The Physiological Society. 
Reprinted with permission. 
  




 GABAA receptor modulation 
GABAergic inhibition can be modulated by many different endogenous and exogenous 
molecules that alter GABA affinity for GABAA receptors, burst frequency and duration of 
the channel, as well as changing the probability of GABA vesicle release from presynaptic 
neurons. Such changes will alter the amplitude and deactivation of IPSCs. For example, 
phenobarbital (a barbiturate) increases burst duration (Twyman et al., 1989). On the other 
hand, diazepam (a benzodiazepine) increases burst frequency by increasing GABA affinity 
for GABAA receptors (Twyman et al., 1989; Sigel & Steinmann, 2012). GABAA receptors 
can also be modulated by protein kinase activities (section 1.2.4) and neurosteroids (section 
1.3), steroids that can alter neuronal excitability.   
 GABAA receptor modulation by protein kinases 
One of the major modulators of GABAA receptor is protein kinase. Various kinases are 
known to phosphorylate GABAA receptor (Nakamura et al., 2015), but this thesis will focus 
on 3 kinases: protein kinase C (PKC), protein kinase A (PKA), and tyrosine receptor kinase 
B (TrkB). The phosphorylation sites on GABAA receptor are in the intracellular domain 
between M3 and M4 transmembrane domains (Huganir & Greengardt, 1990; Chuang & 
Reddy, 2018). The effects of kinases can vary depending on which subunit/residue is 
phosphorylated. Single channel studies have shown that protein kinase activities (and thus 
phosphorylation of GABAA receptor) results in changes to open probability and open 
frequency of the receptor to modulate GABAergic inhibition (Porter et al., 1990; Moss et 
al., 1995; Tang et al., 2010; O’Neill & Sylantyev, 2018).  
PKC is a serine/threonine kinase that has been shown to phosphorylate α4, β1-3, and γ2 
subunits (Kellenberger et al., 1992; Krishek et al., 1994; Brandon et al., 1999; Abramian 
et al., 2014). PKC is typically activated by Gq-coupled GPCRs like 5-HT2 receptors (Feng 
et al., 2001). Below is the summary of the effect of PKC phosphorylation of GABAA 
receptor on IPSC and GABA-induced currents.  
PKC phosphorylates the α4 subunit at serine-443 (S443) to enhance GABAergic tonic 
current in the hippocampus (Abramian et al., 2010). PKC phosphorylation of β1 subunit at 
S409 resulted in decreased amplitude of GABA-induced current in HEK293 cells 
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transfected with α1β1γ2L (Krishek et al., 1994). Phosphorylation of β2 at S410 also resulted 
in decreased GABA-induced current amplitude in oocytes transfected with α1β2γ2S 
(Kellenberger et al., 1992). β3 subunit phosphorylation at S408/S409 resulted in increased 
miniature IPSC amplitude in cortical and hippocampal primary cultures (Jovanovic et al., 
2004). Phosphorylation of γ2 at S327 in transfected oocytes and HEK293 cells resulted in 
decreased GABA-induced current amplitude (Kellenberger et al., 1992; Krishek et al., 
1994). Apart from β3, PKC phosphorylation of GABAA receptors typically suppresses 
GABAergic currents.  
PKA, like PKC, is a serine/threonine kinase. It is activated by cyclic adenosine 
monophosphate (cAMP) and thus is also known as cAMP-dependent protein kinase. PKA 
has been shown to phosphorylate β1 and β3 subunits (Moss et al., 1992; Krishek et al., 1994; 
Terunuma et al., 2004). While the β2 subunit contains the conserved serine residue (S410) 
that can be phosphorylated by many kinases including PKA and PKC, in vivo experiments 
have shown that this residue in β2 subunit is not phosphorylated by PKA (McDonald & 
Moss, 1997; McDonald et al., 1998). 
PKA phosphorylation at S409 of β1 subunit resulted in decreased amplitude of GABA-
induced current in HEK293 cells transfected with α1β1γ2 receptors (Moss et al., 1992). 
Phosphorylation of β3 subunit at S408/S409 resulted in increased amplitude of GABA-
induced current in transfected HEK293 cells and in hippocampal CA3 neurons (McDonald 
et al., 1998; Terunuma et al., 2004).  
TrkB is a receptor for brain-derived neurotrophic factor (BDNF). It phosphorylates 
tyrosine residues. TrkB has been shown to phosphorylate β3 and γ2 subunits (Jovanovic et 
al., 2004; Nakamura et al., 2015). Previous studies have shown that TrkB can also activate 
PKC signaling (Jovanovic et al., 2004). While phosphorylation of tyrosine residues on 
other subunits have been identified by mass spectrometric analysis (β1 at Y230, β2 at 
Y215), it is unclear whether these sites are phosphorylated by TrkB or other tyrosine 
kinases like Src and Fyn (Kang et al., 2011).  
TrkB phosphorylation of β3 subunit is mediated by activation of PKC signaling, resulting 
in phosphorylation of S408/S409, resulting in transient increase in mIPSC amplitude, 
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followed by dephosphorylation and depression of mIPSC amplitude (Jovanovic et al., 
2004). Phosphorylation of Y365/367 of γ2 subunit by BDNF resulted in sustained increase 
in mIPSC amplitude and frequency (Vithlani et al., 2013).  
Protein kinases can be activated by various endogenous signaling molecules, such as 
hormones, neurotransmitters, and growth factors (Schulman, 2004). For example, GPCRs 
(which include receptors for various neurotransmitters, hormones, and growth factors) can 
activate/inhibit protein kinase activities via their Gα subunits (Gutkind, 1998; Pfleger et al., 
2019). PKA can be activated by GS-coupled receptors (e.g. glucagon receptor, corticotropin 
releasing factor receptor) which activate adenylyl cyclase to produce cAMP (Rall & 
Sutherland, 1962; Pfleger et al., 2019), and it can be inhibited by Gi-coupled receptors (e.g. 
GABAB receptor) that inhibit adenylyl cyclase activity (Chen & Iyengar, 1993; Taussig et 
al., 1993). PKC can be activated by Gq/11-coupled receptors (e.g. 5-HT2 receptors). Gq/11 
activates phospholipase C to produce diacylglycerol, which activates PKC (Kaibuchi et al., 
1981; Lee et al., 1992). TrkB can be activated by its main ligand BDNF and other 
neurotrophic factors like neurotrophin-4 (Naylor et al., 2002).  
Activation of protein kinases (and their upstream and downstream signaling) can also lead 
to indirect effects that can alter GABAA receptor function. For example, PKC has been 
shown to enhance synaptic transmission by increasing the pool size of releasable synaptic 
vesicles and Ca2+ affinity of the vesicle release machinery (Wu & Wu, 2001; Berglund et 
al., 2002). As such, PKC activation via Gq coupled receptors (e.g. mGluR1 and mGluR5) 
and phorbol esters (e.g. phorbol 12-myristate 13-acetate; PMA) have been shown to 
enhance release of neurotransmitter vesicles like GABA and enhance IPSC frequency 
(Bartmann et al., 1989; Chu & Hablitz, 1998; Majewski & Iannazzo, 1998). Gq mediated 
signaling also increases intracellular Ca2+ via production of  inositol 1,4,5-trisphosphate, 
which can increase probability of vesicle release and increase GABA release (Llano et al., 
2000; Mathew & Hablitz, 2008; de Juan-Sanz et al., 2017). PKA activation (by Gs coupled 
noradrenergic receptors and pharmacological activators like 8-Br-cAMP and forskolin) 
had similar effect where it increased IPSC frequency by modulating the vesicle release 




Neurosteroids are steroids that modulate neuronal excitability, typically by binding to 
GABAA receptors or N-methyl-D-aspartate (NMDA) receptors. The term ‘neurosteroid’ 
was first used by Étienne-Émile Baulieu and Paul Robel, and refers to steroids that are 
synthesized in the brain (Baulieu & Robel, 1990; Mellon, 1994; Reddy, 2010).  They are 
derived from sex or stress hormones such as deoxycorticosterone, pregnenolone, and 
progesterone and are synthesized in the brain by neurons and glial cells (Reddy, 2010). 
There are two categories of neurosteroids, based on their activity. The first is inhibitory 
neurosteroids, such as tetrahydrodeoxycorticosterone (THDOC), that binds to GABAA 
receptors to enhance their activities. Second is excitatory neurosteroids like pregnenolone 
sulfate (PregS), that can negatively modulate GABAA receptor and enhance NMDA 
receptor function.  
Due to their ability to modulate neuronal excitability, inhibitory neurosteroids like 
alfaxalone and alfadolone are used as general anesthetics in veterinary and human medicine 
(Ramsay et al., 1974; Esmail et al., 1974; Dechêne, 1976). Ganaxolone, another inhibitory 
neurosteroid, has been shown to protect against focal seizures and is being tested for use 
as anti-seizure medication (Reddy & Rogawski, 2002; Kaminski et al., 2004). Synthetic 
excitatory neurosteroids are currently being investigated for possible use in neurological 
disorders involving cognitive, neurological, and behavioral symptoms such as Alzheimer’s 
disease and Huntington’s disease (Blanco et al., 2018; Sage Therapeutics, 2017)  
 Inhibitory neurosteroids & THDOC 
The inhibitory neurosteroid THDOC (3α,21-dihydroxy-5α-pregnan-20-one) is derived 
from deoxycorticosterone (DOC), produced by the adrenal gland (Purdy et al., 1991; 
Strömstedt & Waterman, 1995; Reddy & Rogawski, 2002). DOC is metabolized by 5α-
reductase and 3α-hydroxysteroid dehydrogenase (3α-HSD) to make THDOC (MacKenzie 
& Maguire, 2013).  
THDOC is a potent positive allosteric modulator of GABAA receptor, and it binds to a 
distinct site, away from the benzodiazepine binding site (Majewska et al., 1986; Lambert 
et al., 1990). While earlier studies suggested THDOC binds within the α-helix of the α 
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subunit, recent crystal structure studies show it binds at α-β subunit interface (Hosie et al., 
2006; Laverty et al., 2017; Miller et al., 2017).  
Inhibitory neurosteroids typically prolongs the time course/decay of IPSCs, without 
altering the amplitude (Zhu and Vicini, 1997; Cooper et al., 1999; Harney et al., 2003; Stell 
et al., 2003; Schwabe et al., 2005; Kia et al., 2011). This prolongation of decay is a result 
of enhanced desensitization, as THDOC prolongs the slow desensitization state (Zhu & 
Vicini, 1997). The prolongation of the slow desensitization state results in increased 
number of late channel openings, thereby increasing channel open probability of GABAA 
receptors. 
THDOC has also been shown to enhance tonic inhibition (Stell et al., 2003; Kia et al., 
2011). In fact, studies suggest that δ-subunit containing GABAA receptors are more 
sensitive to neurosteroids than the γ-subunit containing counterparts (Brown et al., 2002; 
Stell et al., 2003).  
At single-channel level, inhibitory neurosteroids are shown to increase frequency of 
channel opening and the duration of channel opening (Lambert et al., 1987, 1995). The 
longer open duration is as a result of neurosteroids increasing the probability of GABAA 
receptor to enter a longer open state (Twyman & Macdonald, 1992; Bianchi & Macdonald, 
2003). In δ subunit-containing receptors, THDOC introduced a long open state that was 
not seen without neurosteroid application (Wohlfarth et al., 2002). These changes summate 
to the macroscopic enhancement of IPSC (prolonged decay/deactivation) and tonic 
inhibition.  
Although inhibitory neurosteroids generally enhance GABAergic transmission, their 
efficacy varies depending on cell type or brain regions. For example, the inhibitory 
neurosteroid 5β-pregnan3α-ol-20-one, at 10-100 nM concentration, prolonged the decay of 
mIPSC in CA1 pyramidal cells, but had no effect in dentate gyrus granule cells (Harney et 
al., 2003); granule cells only responded to much higher 300 nM – 1μM concentration of 
the neurosteroid. In other cases, the same population of cells respond differently to 
neurosteroids depending on disease state or developmental stage (Brussaard et al., 1997; 
Kia et al., 2011). The effects of THDOC was greatly reduced in the pyramidal cell from 
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the piriform cortex in epileptic rats (Gavrilovici et al., 2006; Kia et al., 2011). In the 
supraoptic nucleus, neurons are sensitive to neurosteroid one day prior to parturition, but 
become insensitive 24 hours later (Brussaard et al., 1997). These changes in neurosteroid 
sensitivity have often been attributed to changes in kinase activities (Koksma et al., 2003; 
Kia et al., 2011). Effects of kinases on neurosteroid effect will be discussed further in 
section 1.4 below.  
 Excitatory neurosteroids & PregS 
PregS is an excitatory neurosteroid that is synthesized de novo in the brain. Cholesterol is 
converted to pregnenolone by cytochrome P450 side-chain cleavage enzyme (P450scc), 
and sulfonated by sulfotransferase enzymes SULT2A1, SULT2B1a, and SULT2B1b, to 
form PregS (Tsutsui et al., 2000; Burel et al., 2013; Harteneck, 2013).   
PregS acts as a negative allosteric modulator of GABAA receptors, and it binds to a site 
distinct from that of inhibitory neurosteroid THODC (Laverty et al., 2017a). While the M1 
domain is essential for THDOC binding, PregS interacts with M3 and M4 domain (Akk et 
al., 2008; Laverty et al., 2017).   
Unlike inhibitory neurosteroids that do not alter amplitude, PregS typically reduce the 
amplitude of IPSCs (Majewska et al., 1988; Le Foll et al., 1997; Poisbeau et al., 1999). 
PregS also accelerates the decay of IPSC, further reducing inhibitory function of GABAA 
receptors (Shen et al., 2000). While the effect of PregS on phasic inhibition (IPSCs) has 
been well-established, its effect on tonic inhibition is not well studied. One study showed 
that in ventrobasal complex of the thalamus, eIPSCs of δ subunit deficient mice were 
sensitive to PregS, while the wildtype mice were not, suggesting that δ subunit may confer 
insensitivity to PregS (Porcello et al., 2003). It is suggested that at single channel level, 
PregS reduces the channel opening frequency (Mienville & Vicini, 1989).    
In addition to its ability to suppress GABAergic inhibition, PregS can also enhance 
glutamatergic transmission (Wu et al., 1991; Bowlby, 1993; Petrovic et al., 2009). 
Specifically, PregS acts as a positive allosteric modulator of the NMDA receptor. Studies 
showed that PregS increased the peak amplitude of NMDA-mediated currents in cultured 
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spinal cord neurons, cultured hippocampal pyramidal cells, and HEK293 cells transfected 
with NMDA receptors (Wu et al., 1991; Bowlby, 1993; Petrovic et al., 2009).  
 Protein kinase modulation of neurosteroid effect on 
GABAA receptors 
The efficacy of neurosteroids has been previously shown to be influenced by kinase 
activities in the postsynaptic neurons (Leidenheimer & Chapell, 1997; Kia et al., 2011). 
However, how different kinases, and therefore phosphorylation, alter the effect of 
neurosteroids on GABAA receptor function is not fully understood, as the effects seem to 
differ depending on the cell type and/or brain region. 
 Inhibitory neurosteroids 
Kinases have been shown to have differing effects on modulating neurosteroid-induced 
enhancement of GABAergic currents. In magnocellular neurons of the hypothalamic 
supraoptic nucleus, neurosteroid modulation of sIPSCs was dependent on PKC 
phosphorylation, as PKC antagonist blocked the potentiating effect of neurosteroid 
(Fáncsik et al., 2000). Similarly, in dentate gyrus granule cells, PKC activation increased 
sensitivity of mIPSCs to neurosteroid (Harney et al., 2003). However, in pyramidal cells 
of the piriform cortex (PCtx), PKC activation had an opposite effect, where it reduced the 
efficacy of neurosteroid on mIPSCs (Kia et al., 2011). Xenopus oocytes expressing 
recombinant α1β2γ2L receptors also responded similarly (Leidenheimer & Chapell, 1997).  
PKA inhibition in CA1 neurons and magnocellular neurons has been shown to reduce 
neurosteroid efficacy on mIPSCs (Fáncsik et al., 2000; Harney et al., 2003). To the best of 
our knowledge, there has not been any studies that looked at the effect of TrkB activation 
on neurosteroid modulation of IPSCs. Effects of kinases on tonic inhibition is less studied, 
but a previous study showed that PKC activation in PCtx pyramidal cells suppressed 
THDOC-mediated potentiation of tonic inhibition (Kia et al., 2011). 
 Excitatory neurosteroids 
The effects of kinases on the activity of excitatory neurosteroids are largely unknown, as 
previous studies have only focused on inhibitory neurosteroids. To date, there has not been 
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any studies investigating the effects of kinase activation on effects of PregS-mediated 
modulation of spontaneous GABAergic currents. Only a single study on GABA-induced 
current was conducted, looking at PKC activation in xenopus oocyte transfected with 
α1β2γ2L receptors; they found that PKC activation did not affect the effect of PregS 
(Leidenheimer & Chapell, 1997).  
 Implication for protein kinase & neurosteroid modulation  
Phosphorylation of GABAA receptors play an important role in modulating neuronal 
response to neurosteroids both in normal physiological functioning and in neurological 
disorders. During development, there is a change in neurosteroid sensitivity before and 
after parturition in the neurons of supraoptic nucleus (Lambert et al., 2003). The neurons 
were found to be sensitive to the neurosteroid allopregnanolone, just prior to parturition 
(P20), but they become insensitive just after parturition (PPD1) (Brussaard et al., 1997). 
This sudden change in neurosteroid sensitivity was due to increased PKC activity (Koksma 
et al., 2003). The increased PKC activity was in turn due to increased activation of oxytocin 
receptors (due to increased oxytocin release just prior to parturition). As oxytocin receptors 
are Gq/11-coupled GPCRs, their activation results in activation of PKC (Wang & Hatton, 
2006).  
In epilepsy, studies have found that pyramidal cells in the piriform cortex (PCtx) become 
insensitive to THDOC after kindling, a model of temporal lobe epilepsy (Gavrilovici et al., 
2006). This insensitivity was reversed with phosphatase activation and was found to be due 
to PKC activation, suggesting that changes to GABAA receptor phosphorylation is linked 
to epilepsy (Kia et al., 2011). These examples highlight the impact of protein kinase activity 
on modulating neurosteroid effect in normal and abnormal physiological conditions.  
 Seizure & Epilepsy 
Epilepsy is a neurological disease characterized by recurrent seizures (Fisher et al., 2014). 
Seizure, or epileptic seizure, is the occurrence of transient, excessive hypersynchronous 
discharge in the brain, typically resulting from too much excitation or too little inhibition 
in the brain area (Chang & Lowenstein, 2003; Fisher et al., 2014). Approximately 50 
million people (~0.65% of the world population), suffer from epilepsy worldwide, making 
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it one of the most common neurological diseases (World Health Organization, 2019). 
Symptoms of epilepsy vary widely, depending on the brain region affected (focus), ranging 
from changes in emotion or cognition to uncontrolled muscle movements (Fisher et al., 
2017b). Drug resistance is seen in 20-40% of epilepsy patients, and depending on the type 
of epilepsy, can be higher (Semah et al., 1998; Schmidt & Löscher, 2005; World Health 
Organization, 2005; Jette et al., 2014). 
 Definition & types 
According to the International League Against Epilepsy (ILAE) (Fisher et al., 2014), 
epilepsy is clinically defined by one or more of the following conditions:  
1. Having at least two unprovoked, or reflex, seizures occurring >24 hours apart 
2. Having one unprovoked or reflex seizure and a probability of more seizures 
similar to general recurrence risk (≥ 60%) after two unprovoked seizures 
occurring over the next 10 years (e.g. structural regions from stroke, traumatic 
brain injury) 
3. Having diagnosis of an epilepsy syndrome 
Epilepsy is considered to be resolved if an individual does not have any seizures for 10 
years with the last five years without anti-seizure medications or for age-dependent 
epilepsy syndrome, the individual has past the applicable age for the particular syndrome 
(Fisher et al., 2014).  
There are many different types of seizure, and they have been classified depending on 
region of onset, level of awareness, and prominent symptoms (Figure 1.4) (Fisher et al., 
2017b). First, seizures are classified into focal or generalized onset. Focal seizures 
(previously known as partial seizures) originate in one hemisphere of the brain, whereas 
generalized seizures originate bilaterally (Fisher, 2017). Focal onset seizures are further 
classified as aware or impaired awareness (previously known as simple and complex 
seizures, respectively). Generalized onset seizures typically result in loss of awareness, so 
this classification is not used for them. Both focal and generalized onset seizures can further 
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be classified based on their symptoms including motor onset (tonic, clonic, myoclonic, 
etc.) and non-motor onset (absence, emotional, sensory, etc.).  
Focal impaired awareness seizure (complex partial seizure) is the most common type of 
seizure, and majority of focal seizures originate from the temporal lobe (Gastaut et al., 
1975; Hauser et al., 1993, 1996; Löscher & Schmidt, 1994; Engel & Salamon, 2015). 
Epilepsy characterized by focal seizures originating from the temporal lobe is termed 
temporal lobe epilepsy (TLE) (Engel & Salamon, 2015). While the term TLE is no longer 
recognized by the ILAE (now classified as focal aware/impaired awareness), it is still a 
useful term in research and clinical settings when discussing focal seizures originating from 






Seizure classification by the International League Against Epilepsy. Seizures are classified 
based on region of onset, followed by awareness level. Seizures are further classified by 
motor or nonmotor symptoms. If onset is known, seizures are classified based on the 
motor/nonmotor symptoms. If information about seizure is inadequate to place it in other 
categories, it is considered unclassified. 
Reprinted from “Instruction manual for the ILAE 2017 operational classification of seizure 
types” by R. S. Fisher et al. 2017. Epilepsia 58.4:531-542. Wiley Periodicals, Inc. 
Copyright © 2017 International League Against Epilepsy. Reprinted with permission. 
 
  
Figure 1.4 Classification of seizure types 
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 Temporal lobe epilepsy 
TLE is the most common form of focal epilepsy, and is often pharmacoresistant (Téllez-
Zenteno & Hernández-Ronquillo, 2012; Sharma et al., 2015). TLE most commonly 
involves the mesial temporal lobe, which includes the amygdala, hippocampus, and 
parahippocampal gyrus (Engel, 2001). One of the most common pathologies of mesial TLE 
(mTLE) is hippocampal sclerosis (HS)  (Cendes, 2005; Engel & Salamon, 2015). Other 
pathologies include lesions in other structures of mesial temporal lobe, genetics, cortical 
malformation/dysplasia, vascular malformations, hamartomas, and tumours (Shinoda et 
al., 2004; Cendes, 2005; Al Sufiani & Ang, 2012).  
HS is defined as the loss of neurons and glia in CA1 and CA4 of the hippocampus (Wieser, 
2004). Studies have shown that HS is implicated with prolonged febrile seizures in early 
life (Maher & McLachlan, 1995). Typically in HS, there is severe pyramidal cell loss in 
CA1 with less prominent losses in CA3 and CA4 (Al Sufiani & Ang, 2012). Glial 
proliferation (astrocytes) is a prominent feature of HS and mTLE and is thought to be 
involved in high levels of glutamate found in hippocampus in TLE patients (Eid et al., 
2008; Al Sufiani & Ang, 2012). Sclerosis that involves not only the hippocampus and other 
regions of the temporal lobe (amygdala and entorhinal cortex) is termed medial temporal 
sclerosis.  
Neocortical TLE (nTLE) is another type of TLE that primarily involves lateral/neocortical 
temporal lobe. nTLE is not as well-defined as mTLE; it is less prevalent, and it often 
propagates to mesial temporal lobe structures, making it difficult to differentiate between 
mTLE and nTLE (Schramm et al., 2001; Bercovici et al., 2012). However, studies have 
shown that nTLE patients are less likely to have ictal symptoms, and more likely to have 
auditory hallucinations and ambiguous onset/offset of seizures (Lee et al., 2006; Bercovici 
et al., 2012). Another distinguishing feature is that nTLE seizures are typically shorter than 
mTLE (46 vs. 68 sec) (Foldvary et al., 1997).   
 GABA in epilepsy 
Numerous changes to GABAA receptors are seen in epilepsy. In the hippocampi of TLE 
patients, there are marked changes to GABAA receptor expressions (Loup et al., 2000). 
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CA1, CA3, and the hilus of hippocampus showed decreased GABAA receptor subunit 
staining, suggesting loss of interneurons. There were also changes to α1 subunit expression 
and loss of α1 subunit. In animal models of epilepsy, expressions of δ subunits in dentate 
gyrus cells and α5 subunits in CA1 have been shown to decrease (Houser & Esclapez, 2003; 
Peng et al., 2004; Nishimura et al., 2005).  
Many antiepileptic drugs target GABAergic transmission either directly, by positive 
modulation of GABAA receptor (barbiturates, benzodiazepines) or indirectly by altering 
GABA reuptake or breakdown (Tiagabine, Vigabatrin) (Rogawski & Löscher, 2004; 
Löscher & Rogawski, 2012; Ochoa & Kilgo, 2016).  
Mutations of GABAA receptor subunits have been implicated in several different types of 
epilepsies. Mutations of α1 subunit gene are linked to juvenile myoclonic epilepsy and 
childhood absence epilepsy (Cossette et al., 2002; Maljevic et al., 2006). Mutations or 
deletions of γ2 subunit gene are implicated in generalized epilepsy with febrile seizure plus 
(GEFS+), childhood absence epilepsy and febrile seizures (Harkin et al., 2002; Kananura 
et al., 2002; Audenaert et al., 2006). There are also other mutations that affect trafficking 
or cell surface expression of the receptor (Fritschy, 2008).  
 Animal model of Epilepsy – Kindling 
The kindling model is one of the most commonly used animal model of chronic TLE 
(Morimoto et al., 2004). Electrical stimulation of the limbic region, including the 
hippocampus, amygdala, and PCtx, results in focal seizures, and repeated 
stimulation/seizure results in progressively more severe seizure response, eventually 
reaching full motor seizure with rearing and falling (Goddard, 1967; Racine, 1972a). This 
progressive worsening of seizure symptoms is termed kindling. Seizure severity in 
experimental animals is typically graded based on the Racine scale, ranging from stage 1 
to 5 (Racine, 1972a). We used a modified Racine scale to score the seizures seen in our 
rats. Stage 1 seizure involves behaviour arrest (freezing), sniffing, and mouth twitches. 
Stage 2 seizures show more severe facial clonus and head nodding. In stage 3, there is 
unilateral forelimb clonus, contralateral to stimulation electrode. Stage 4 involves bilateral 
forelimb clonus and rearing. Lastly, in stage 5, rearing and falling with generalized tonic-
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clonic seizure is seen. The animal is considered fully kindled once it reaches stage 5 
(Gavrilovici et al., 2006).  
As the seizures get more severe with repeated stimulation, the stimulation threshold to elicit 
a seizure decreases (Racine, 1972b). Past studies have suggested that kindling-like 
phenomena occurs in human TLE (Engel, 1996; Coulter et al., 2002). As such, kindling 
model has been widely used to screen antiepileptic drugs and to study the mechanisms of 
epilepsy (Otsuki et al., 1998; Morimoto et al., 2004; Gavrilovici et al., 2006; Kia et al., 
2011; Ashraf et al., 2013; Birjandian et al., 2013). While kindling is typically done by 
stimulating the hippocampus and the amygdala, PCtx can also be stimulated to kindle 
animals (McIntyre et al., 1999). Some studies have suggested that PCtx activation is 
required for the development of generalized seizures in kindling (Morimoto et al., 2004).  
 The piriform cortex (PCtx) 
PCtx is a major part of the olfactory cortex and is involved in olfaction and memory 
(Johnson et al., 2000). It is a part of the paleocortex, which is phylogenetically old structure 
with three cell layers, unlike six in the neocortex (Haberly, 1990; Aboitiz et al., 2003; 
Fontanini, 2009). As it is an old structure, the PCtx is well-conserved across different 
species (Vaughan & Jackson, 2014). The term piriform comes from the appearance of PCtx 
in cats, where it resembles the shape of a pear (pirum in Latin) (Löscher and Ebert, 1996). 
In humans, PCtx is located at the ventromedial surface of the cortex at the junction of 
frontal and temporal lobe and is small compared to that of other mammals like rats, in 
which it can take up to 10% of cortical volume (Löscher and Ebert, 1996; Illig and Wilson, 
2009; Vaughan and Jackson, 2014). This thesis will focus on the rat PCtx.   
 Structures of the PCtx 
PCtx consists of three layers: layer I, II, and III. Layer I is the most superficial layer of the 
PCtx and contains mostly axons and dendrites that connect the PCtx to other parts of the 
olfactory cortex, with very few somas (Suzuki & Bekkers, 2007). Layer I is further 
subdivided into Ia and Ib. Layer Ia contains axons from the lateral olfactory tract (LOT), 
and layer Ib receives inputs from within the PCtx and other structures of the olfactory 
cortex (Suzuki & Bekkers, 2007; Illig & Wilson, 2009). Layer II is densely populated by 
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pyramidal cells, and it is sometimes subdivided into layer IIa and IIb. Layer IIa contains 
specialized pyramidal cells called semilunar cells, and layer IIb contains somas of 
pyramidal cells (Illig & Wilson, 2009). Layer III contains deep pyramidal cells and 
multipolar neurons. Deep to layer III is the endopiriform nucleus, which is sometimes 
referred to as layer IV of the PCtx (O’Leary, 1937; Tseng & Haberly, 1989). It contains 
multipolar neurons that projects to the PCtx (particularly to layer III) as well as other parts 
of the cortex (Behan and Haberly, 1999; Birjandian et al., 2013).  
 Connections to and from the PCtx 
The main input to the PCtx is from the olfactory bulb via LOT (Price, 1973); the axons 
from LOT synapse with apical dendrites of Layer II pyramidal cells in Layer Ia. These 
connections are glutamatergic, and as such, excitatory (Collins & Howlett, 1988). PCtx 
neurons are also strongly interconnected (Haberly, 1985; Birjandian et al., 2013). PCtx 
receive input from contralateral PCtx as well (Wilson, 1997). PCtx is highly connected to 
the entorhinal cortex and the perirhinal cortex (Luskin & Price, 1983; Agster & Burwell, 
2009; Vismer et al., 2015). Other connections include the amygdala, subiculum, and the 
orbitofrontal cortex (Krettek and Price, 1978a; Wakefield, 1980; Luskin and Price, 1983; 
Carmichael et al., 1994). 
 PCtx & Epilepsy 
Owing to its numerous connections with other epileptogenic areas of the brain (amygdala, 
hippocampus, and entorhinal cortex), PCtx is extremely susceptible to seizure generation 
(Löscher and Ebert, 1996; Vaughan and Jackson, 2014). Area tempestas, located in anterior 
PCtx, is thought to be the most seizure-susceptible area in the brain. It shows extreme 
sensitivity to proconvulsants, as picomolar concentrations of bicuculline and kainic acid 
could elicit bilateral clonic seizures (Piredda & Gale, 1985; Gale, 1988; Vaughan & 
Jackson, 2014). It is also very susceptible to kindling (McIntyre et al., 1999). In fact, PCtx 
kindles faster than the hippocampus and amygdala, and some studies have suggested that 
PCtx activation is required to generate generalized seizures in kindling (McIntyre et al., 
1999; Morimoto et al., 2004; McIntyre & Gilby, 2008).  
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The PCtx in epileptic animal shows numerous changes in its neuronal characteristics. 
Kindling results in loss of functional diversity of interneurons, with limited firing patterns 
(Gavrilovici et al., 2012). There are also changes to CRF signaling, in which CRF, normally 
inhibitory in the PCtx, becomes excitatory after kindling and making the brain more 
susceptible to seizures (Narla et al., 2016). Lastly, the layer II pyramidal cells become 
insensitive to neurosteroid THDOC after kindling (Kia et al., 2011).   
 PCtx circuit 
The changes of PCtx in epilepsy mentioned above involve a unique feed-forward 
disinhibitory circuit (Figure 1.5) (Birjandian et al., 2013). The circuit consists of layer II 
and III of the PCtx and the dorsal endopiriform nucleus (DEn). The layer II pyramidal cells 
project to interneurons in DEn. In turn, the DEn interneurons project to layer III 
interneurons, and the layer III interneurons project to layer II pyramidal cells. Thus, 
excitation of the layer II pyramidal cells (via stimulation of their apical dendrites in LOT), 
activates the inhibitory interneurons of DEn, which then inhibit the layer III interneurons. 
This disinhibition (inhibition of inhibitory neurons) means a reduced inhibition of the layer 
II pyramidal cells, which augments the excitability of PCtx, creating a feed-forward loop. 
After kindling, the disinhibition became stronger, increasing the excitability of the circuit 





Figure 1.5 The piriform cortex circuit 
Schematic diagram of the piriform cortex circuit involving the lateral olfactory tract (LOT), 
piriform cortex, and the dorsal endopiriform nucleus (Den). Stimulation of LOT results in 
activation of layer II pyramidal cells via their apical dendrites (A) in layer I. Layer II 
pyramidal cells activates Den interneurons (B). In turn, Den interneurons inhibit layer III 
interneurons (C), resulting in disinhibition. As a result of the disinhibition, layer II 
pyramidal cells (D) receive reduced inhibition. This feed-forward disinhibition enhances 
the strength of stimuli from the LOT.    
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 Thesis Overview 
Despite its importance, the effects of kinase interaction with neurosteroids on GABAA 
receptor is not well understood. Furthermore, the effect of kinase activation, neurosteroids, 
and their interactions have not been investigated in the PCtx circuit, and how they will 
change in epilepsy is also unknown. Thus, the main objective of this thesis was to 
determine the effects of kinase activators on neurosteroid-induced modulation of inhibitory 
transmission at cellular- and circuit-level, and how these change in epilepsy. This thesis 
investigatad the following aims: 
1. Characterize the effects of kinase activation on neurosteroid-induced modulation 
of GABAA receptor mediated currents. 
2. Investigate the effects of kinase activation, THDOC, and their interaction in the 
PCtx circuit. 
3. Investigate the effects of kinase activation, THDOC, and their interaction in 
epileptic PCtx circuit. 
Specifically, we studied the effects of the inhibitory neurosteroid THDOC and excitatory 
neurosteroid PregS on GABAA receptor-mediated mIPSCs and tonic inhibition and how 
their effects were altered by protein kinase activation. We also studied how THDOC and 
activation of protein kinases alter the activity of PCtx circuit using VSDI, and how their 
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Chapter 2  
2 Kinases differentially modulate the action of neurosteroid 
THDOC on phasic and tonic GABAA receptor currents 
 Introduction 
GABAA receptors, activated by the neurotransmitter GABA, mediate inhibition in the 
central nervous system (CNS). They are heteropentamers made from 19 different subunits: 
α(1-6), β(1-3), γ(1-3), δ, ε, π, θ, and ρ(1-3) (Olsen & Sieghart, 2009; Stefanits et al., 2018). A 
typical synaptic receptor consists of two α, two β, and one γ subunits (Whiting et al., 1999) 
and mediate phasic inhibition in response to GABA release in the synaptic cleft. The δ 
subunit-containing receptors (with two α and two β subunits) are localized to extrasynaptic 
membrane and have high affinity to GABA (Wei et al., 2003; Farrant & Nusser, 2005). 
Thus, these extrasynaptic receptors are activated by low ambient GABA concentration in 
extrasynaptic space and mediate persistent conductance, which is termed tonic inhibition 
(Brickley & Mody, 2012). Tonic inhibition sets the overall “tone” of the excitability of the 
cell and has been shown to play a major role in modulating γ oscillation (Farrant & Nusser, 
2005; Mann & Mody, 2009).  
The activity of the GABAA receptor is modulated by many exogenous and endogenous 
molecules. In particular, neurosteroids, metabolites of endogenous steroids, are known to 
modulate GABAA receptor-mediated inhibition in the CNS, perhaps controlling or fine 
tuning the physiological functioning of GABAA receptors (Fritschy, 2008). Neurosteroids 
are also implicated in numerous neurological and psychiatric disorders, including epilepsy, 
mood disorders, and anxiety (Reddy, 2003; Mann & Mody, 2009; Brickley & Mody, 2012). 
Thus, information about how GABAA receptor is modulated by neurosteroids is essential 
not only in comprehending the physiology of the CNS, but also in better understanding the 
pathophysiology of various neurological and psychiatric disorders.  
Neurosteroids are known to modulate both phasic and tonic inhibition. Positive allosteric 
modulator neurosteroids, such as tetrahydrodeoxycorticosterone (THDOC), potentiate 
GABAA receptor synaptic (phasic) activity by prolonging the decay of inhibitory 
postsynaptic currents (IPSCs) (Schwabe et al., 2005; Kia et al., 2011). This prolongation 
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of decay results in greater charge transfer, enhancing inhibition by IPSCs. THDOC also 
enhances tonic inhibition by increasing open duration of δ subunit-containing receptors 
(Wohlfarth et al., 2002).  
Past studies have shown that the effect of neurosteroids can be influenced by the activities 
of kinases in the postsynaptic neurons (Leidenheimer & Chapell, 1997; Kia et al., 2011). 
However, how kinases activity modulate neurosteroids actions on GABAA receptor 
function is complex and not fully understood. For example, neurosteroids have varying 
efficacy on miniature IPSCs (mIPSCs) for different GABAA receptor populations and/or 
cell types (Harney et al., 2003; Lambert et al., 2003; Kia et al., 2011). In the hippocampus, 
protein kinase C (PKC) enhanced the effects of a positive neurosteroid 5β-pregnan-3α-ol-
20-one in slowing the decay of mIPSCs in a cell-type specific manner (Harney et al., 2003). 
On the other hand, in the pyramidal cells of the piriform cortex, we previously reported 
that THDOC potentiates both synaptic and extrasynaptic GABAA receptor currents and 
that PKC activation suppressed the potentiating effects of THDOC (Kia et al., 2011). Of 
note, PKC-mediated suppression of THDOC modulation takes place after kindling, a 
model of temporal lobe epilepsy (Kia et al., 2011). Kinase modulation of neurosteroids 
also occur during development. The supraoptic nucleus neurons are sensitive to 
neurosteroid one day prior to parturition, but become insensitive 24 h later (Brussaard et 
al., 1997). This rapid change in the sensitivity to neurosteroid was due to PKC activation 
(Koksma et al., 2003). Thus, it appears that phosphorylation state of GABAA receptors play 
important (patho)physiological roles in controlling neurosteroid’s ability to modulate 
inhibition. Yet, it is still not well understood what effects different kinases will have on 
neurosteroid modulation.  
In the present study, we investigated the effects of PKC, protein kinase A (PKA), tyrosine 
receptor kinase B (TrkB) activators on THDOC-mediated modulation of GABAA receptor 
mIPSCs and tonic currents in cortical pyramidal cells. These kinases have been shown to 
modulate GABAA receptor function (Kittler & Moss, 2003). 
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 Materials and Methods 
All experiments were performed in accordance with the guidelines of Canadian Council on 
Animal Care and approved by the University of Western Ontario Animal Care Committee 
(AUP 2014-037). 
 Primary Neuronal Culture 
Pups from pregnant Sprague-Dawley rats (Charles River Laboratories, Quebec, Canada) 
were used to make primary neuronal culture. The pregnant rats were singly housed with ad 
libitum access to food and water under 12-hour light/dark cycle. Minimum of 5 different 
pregnant rats were used per treatment group. The pregnant rats (embryonic day 18) were 
anesthetized by isoflurane and sacrificed by cervical dislocation to quickly isolate the 
embryos. The embryos were then decapitated to isolate portions of developing cortex. The 
isolated brain portions were mechanically dissociated and plated in Neurobasal media with 
B-27 supplement and 2 mM L-glutamine (21103-049, 17504-044, Gibco, ThermoFisher 
Scientific, Waltham, MA, USA). Isolated cells were plated at a density of 1 million 
cells/mL on Nunc 35-mm cell culture dish (1256590, ThermoFisher Scientific) treated with 
poly-D-lysine (P6407, Sigma-Aldrich, St. Louis, Mo, USA). The plated cells were 
incubated for minimum of 14 days for maturation. Media change occurred 3 times a week.  
 Solutions 
Electrophysiological recordings were conducted in external solution containing: 140 mM 
NaCl, 10 mM HEPES, 4.5 mM KCl, 0.5 mM CaCl2, 4 mM MgCl2, and 15 mM D-glucose 
(300-310 mOsm, pH 7.3). To isolate for mIPSCs, action potentials and glutamatergic 
transmissions (AMPA/kainite and NMDA) were blocked with 20 μM DL-2-amino-5-
phosphonopentanoic acid (DL-AP5; 0105, Tocris Bioscience, Bristol, UK), 20 μM 6-7-
dinitroquinoxaline-2,3-dione (DNQX; D0540, Sigma-Aldrich), and 200 nM tetrodotoxin 
(T-550, Alomone Labs, Jerusalem, Israel). The electrode solution consisted of: 145 mM 
CsCl, 0.3 mM CaCl2, 3 mM Na2EDTA, 10 mM HEPES, and 1 mM MgATP (295-305 
mOsm, pH 7.2–7.3). THDOC (P2016, Sigma-Aldrich) was dissolved in 100% ethanol 
(EtOH) at 10 mM, and this stock was diluted to final concentration of 100 nM in the 
external solution (final EtOH 0.001%). Kinases that have been identified to phosphorylate 
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GABAA receptors, and thus investigated are PKA, PKC, and TrkB. 20 µM forskolin 
(F3917, Sigma-Aldrich) was used to activate adenylate cyclase to increase cyclic adenosine 
monophosphate (cAMP), which activates PKA. PKC was activated by 100 nM phorbol 12-
myristate 13-acetate (PMA; 1201, Tocris Bioscience), and TrkB by 20 µM 7,8-
dihydroxyflavone (7,8-DHF; 3826, Tocris Bioscience). Forskolin and PMA were applied 
intracellularly, as application of either drug in bath resulted in large increase in mIPSC 
frequency to the point where individual mIPSCs could not be cleanly resolved. These were 
likely the effects of presynaptic actions of PKC and PKA on intracellular Ca2+ levels, 
vesicle release mechanisms, and vesicle release probability (Bartmann et al., 1989; 
Majewski & Iannazzo, 1998; Llano et al., 2000; Wu & Wu, 2001; Berglund et al., 2002; 
Mathew & Hablitz, 2008). Limiting the exposure of the two kinase activators to the cell 
being patched (and perhaps a few neighbouring cells) eliminated the presynaptic effects 
7,8-DHF was applied in the bath.  
 Electrophysiology and Analysis 
Whole-cell voltage clamp recordings were obtained from morphologically identified 
pyramidal cells clamped at −60 mV. Recordings were performed at room temperature (22-
25 °C) (Schwabe et al., 2005). Recordings were made with an Axopatch 200B amplifier 
(Molecular Devices, San Jose, CA, USA). The recordings were digitized by Digidata 1550 
Digitizer controlled by pCLAMP 10 software suite (Molecular Devices) at 10 kHz (low-
pass filtered at 2 kHz). The electrode resistance was between 5 and 10 MΩ. Series 
resistance was < 20 MΩ with 70–80% compensation. Analysis of spontaneous mIPSCs 
was done using Clampfit 10.5 (Molecular Devices). To minimize dendritically filtered 
events, all events that were analyzed had rise time < 2.5 ms. Each recording was averaged 
from minimum of 20 mIPSC traces. 
IPSC parameters that were analyzed are amplitude, decay constants (τ), fractional 
amplitude contribution, and the amount of charge transferred. The decay of GABAA 
receptor mIPSCs are often biphasic (Verdoorn, 1994; Ing & Poulter, 2007; Kia et al., 2011), 
and the mIPSCs we obtained were best fitted with biphasic exponential curve. The first 
component of decay (τ1) is fast, and the second component is slow (τ2). The decay curves 
of mIPSCs were fitted with standard exponential function found in Clampfit 10.5: 
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∑ /  (Otis & Mody, 1992; Zhu & Vicini, 1997; Hutcheon et al., 2000). 
Fractional amplitude contribution was calculated for τ1 (a1) as A1/(A1 + A2) where A1 is the 
amplitude of τ1 and A2 is the amplitude of τ2 (Mørkve & Hartveit, 2009). a1 represents how 
much τ1 accounts for the whole of decay. For example, a1 of 0.3 means that τ1 is responsible 
for the decay of 30% of the amplitude, whereas τ2 is responsible for remaining 70%. Charge 
transfer was calculated as area under the curve of mIPSC.  
Tonic currents were calculated from Gaussian fit to all-point histograms of amplitude. 
Histograms were created from 10-15 s of data from gap free recordings (bin width 1 pA) 
before and after THDOC application. Gaussian curve was fitted to the portion of all-point 
histogram not skewed by mIPSCs (Glykys & Mody, 2007). The difference between the 
peak amplitude values from the Gaussian fit pre- and post-THDOC applications were used 
to calculate the change in tonic inhibition. 
 Statistical analysis 
Anderson-Darling test was performed to assess the normality of data. The changes in 
mIPSC kinetics (amplitude, time constants, charge transfer) were evaluated using a paired 
t-test for parametric data and Wilcoxon matched-pairs signed rank test for non-parametric 
data on Prism 8.3.0 (GraphPad Software Inc., San Diego, CA, USA). For comparison of 
change in tonic inhibition, one-way ANOVA, followed by Tukey’s multiple comparisons 
test was used for parametric data and Kruskal-Wallis test, followed by Dunn’s multiple 
comparisons test was used for non-parametric data. The significance was set at P < 0.05 
for all statistical tests. All data are expressed as mean ± SEM. 
 Results 
 Kinases subtly alter the effects of THDOC on mIPSCs 
While THDOC has been known to positively modulate GABAA receptor functions in 
various preparations and brain areas (Majewska et al., 1986; Puia et al., 1990; Le Foll et 
al., 1997; Wohlfarth et al., 2002; Schwabe et al., 2005; Kia et al., 2011), its effects could 
vary depending on the cell-types and their conditions (Jussofie, 1993; Cooper et al., 1999). 
Thus, we first investigated the effects of THDOC on mIPSCs of pyramidal cells from 
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primary cortical neuronal culture in rats. After obtaining stable baseline recordings of 
mIPSCs, we applied 100 nM THDOC in the bath and analyzed mIPSCs between 5-10 min 
after drug application. This concentration of THDOC was chosen  based on previous 
studies reporting its modulatory effects on GABAergic currents (Cooper et al., 1999; 
Lambert et al., 2003; Belelli and Lambert, 2005; Schwabe et al., 2005; Kia et al., 2011). 
Recent reports have shown that THDOC can have metabotropic action on GABAA 
receptors via membrane progesterone receptor (Modgil et al., 2017; Parakala et al., 2019). 
However, these studies showed that the metabotropic action of neurosteroid is slow acting 
and only evident after prolonged exposure. The mIPSCs we obtained were  best fitted with 
biexponential curve, as has been demonstrated in other neuronal preparations (Verdoorn, 
1994; Jones & Westbrook, 1995; Kia et al., 2011).  
We observed that 100 nM THDOC greatly potentiated mIPSCs as seen in two-fold increase 
in the charge transfer (−2.29 ± 0.31 vs. −4.97 ± 0.33 pC, P < 0.0001, n = 12 cells, Figure 
2.1). Specifically, THDOC has no effect on amplitude (−52.3 ± 5.1 vs. −54.1 ± 3.2 pA), 
but it greatly prolonged slow decay time constant (τ2. 55.7 ± 3.0 vs 130.6 ± 6.9 ms, P < 
0.0001) while modestly but significantly shortened fast decay time constant (τ1, 9.4 ± 0.6 
vs. 7.4 ± 0.4 ms, P < 0.05). In addition, THDOC increased the fractional amplitude 
contribution of fast decay a1 (see Materials and Methods for details) (0.26 ± 0.02 vs. 0.38 
± 0.02, P < 0.05).   
Next, we investigated whether PMA (100 nM), an activator of PKC, alters the effect of 
THDOC on mIPSCs. PKC is known to phosphorylate β1-3 and γ2 subunits (Kellenberger et 
al., 1992; Krishek et al., 1994; Brandon et al., 1999). PMA did not alter the effect of 
THDOC on mIPSCs (Figure 2.2). There was no significant change in amplitude (−46.6 ± 
3.5 vs. −48.9 ± 3.5 pA, n = 11). Similar to in the absene of PMA, THDOC increased charge 
transfer about 2-fold (−2.09 ± 0.19 vs. −4.08 ± 0.50 pC, P < 0.0001). This was accompanied 
by a shortening of τ1 (11.6 ± 1.2 vs. 7.6 ± 0.6 ms, P < 0.01), prolongation of τ2 (62.4 ± 2.6 




Next, we tested the effect of forskolin (20 µM) on the THDOC-induced mIPSC 
modulation. Forskolin increases PKA activity by activation of adenylyl cyclase. Adenylyl 
cyclase synthesizes cAMP, which activates PKA. PKA has been shown to phosphorylate 
β2 and β3 subunits (Moss et al., 1992; McDonald et al., 1998). Overall, the effects of 
forskolin on THDOC-induced potentiation of mIPSCs was similar to that PMA, resulting 
in about 2-fold increase in charge transfer (−2.47 ± 0.26 vs. −5.13 ± 0.45 pC, P < 0.0001, 
n = 22, Figure 2.3). However, exceptions were the changes in amplitude and τ1. After 
forskolin exposure, THDOC significantly increased the amplitude (−50.2 ± 2.8 vs. −57.2 
± 3.0 pA, P < 0.01,) and did not change τ1 (7.84 ± 0.83 vs. 7.82 ± 0.77 ms, P = 0.77). The 
rest of the mIPSC parameters were similar to that of THDOC alone, with longer τ2 (59.9 ± 
2.9 vs 132.1 ± 7.8 ms, P < 0.0001) and greater a1 (0.25 ± 0.02 vs 0.39 ± 0.01, P < 0.0001).  
We next investigated the effect of the TrkB agonist 7,8-DHF on the effect of THDOC 
(Figure 2.4). TrkB, which acts as a receptor for brain-derived neurotrophic factor, is 
thought to phosphorylate β3 and γ2 subunits (Jovanovic et al., 2004; Nakamura et al., 
2015a). Again, the overall effects of 7,8-DHF on the THDOC-induced mIPSC potentiation 
was similar to that of the untreated control, resulting in about two-fold increase in the 
charge transfer (−2.20 ± 0.21 vs. −4.56 ± 0.63 pC, P < 0.0001, n = 15, Figure 2.4). One 
exception was the small but significant increase in the amplitude (−45.6 ± 3.3 vs. −51.8 ± 
4.5 pA, P < 0.05). All other parameters were similar to that of non-kinase response with τ1 
becoming significantly shorter (8.45 ± 1.29 vs. 5.68 ± 0.25 ms, P < 0.05), τ2 becoming 
longer (58.6 ± 4.1 vs. 113.8 ± 8.1 ms, P < 0.0001), a1 becoming greater (0.30 ± 0.02 vs. 
0.41 ± 0.02, P < 0.01). 
Lastly, we compared the mIPSC parameters before THDOC applications, as kinase 
activation can also affect GABAergic currents. We did not find any significant changes by 
the three kinase treatments when compared to no-kinase control in all parameters (Table 
2.1). Only for τ1, there was small, but significant difference between PMA compared to 7,8-
DHF (P < 0.05). 
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In summary, THDOC robustly potentiated mIPSCs by increasing the charge transfer in the 
pyramidal cells of primary cortical neuronal culture. Overall, the effects of THDOC did 










(A) Representative tracings of control mIPSC with THDOC (B) Average amplitude of 
mIPSCs was unchanged in the presence of THDOC. (C) THDOC shortened fast decay 
constant (τ1), (D) but prolonged slow decay constant (τ2). (E) The fractional amplitude 
contribution of τ1 (a1) also increased significantly. (F) Amount of charge transferred 
increased significantly with the application of THDOC. (*P < 0.05, **P < 0.01 ****P < 
0.0001)  





Figure 2.2 PMA did not alter the effect of THDOC on mIPSCs. 
(A) Representative tracing of mIPSCs. (B) Average amplitude of mIPSCs was unchanged 
in the presence of THDOC. (C) THDOC shortened fast decay constant (τ1), (D) but 
prolonged slow decay constant (τ2). (E) fractional amplitude contribution of τ1 (a1) also 
increased significantly. (F) Amount of charge transferred increased significantly with the 




Figure 2.3 THDOC significantly increased the amplitude of mIPSCs but did not affect 
τ1 when applied after forskolin treatment.  
(A) Representative tracings of mIPSCs. (B) THDOC significantly increased the amplitude 
of mIPSCs in presence of forskolin. (C) THDOC did not alter the fast decay constant (τ1) 
(D) Slow decay constant (τ2) was significantly larger when THDOC is applied in the 
presence of forskolin. (E) Fractional amplitude contribution of τ1 (a1) also increased 







Figure 2.4 THDOC significantly increased amplitude in the presence of 7,8-DHF. 
(A) Representative tracings of mIPSCs. (B) THDOC significantly increased the amplitude 
of mIPSCs. (C) THDOC shortened the slow decay constant (τ1) (D) Slow decay constant 
(τ2) was significantly larger when THDOC is applied. (E) Fractional amplitude 
contribution of τ1 (a1) also increased significantly. (F) Amount of charge transfer increased 
















(n = 12) 
−52.3 ± 5.1 9.4 ± 0.6 55.7 ± 3.0 0.26 ± 0.02 −2.29 ± 0.31 
PMA 
(n = 11) 
−46.6 ± 3.5 11.6 ± 1.2 62.4 ± 2.6 0.31 ± 0.03 −2.09 ± 0.19 
Forskolin 
(n = 22) 
−50.2 ± 2.8 7.8 ± 0.8 59.9 ± 2.9 0.25 ± 0.02 −2.47 ± 0.26 
7,8-DHF 
(n = 14) 
−44.4 ± 3.4 7.4 ± 0.8* 57.0 ± 4.1 0.28 ± 0.02 −2.14 ± 0.22 
 




 Kinases suppress the effect of THDOC on tonic inhibition 
Tonic inhibition, mediated by δ subunit containing GABAA receptors, controls the overall 
excitability of neurons. To measure changes in tonic inhibition, we calculated the 
difference of the holding current before and after 5 min 100 nM THDOC perfusion. The 
holding currents were calculated from all-point histograms from 10-15 s of gap free 
recordings before and after THDOC application by performing Gaussian fits (Figure 2.5). 
Grubb’s test was performed to rule out 2 outlier values because of abnormal rise in holding 
current.  
Application of THDOC alone resulted in holding current dropping by 56.1 ± 8.7 pA (n = 
18), indicating a large enhancement of tonic inhibition by THDOC (Figure 2.6). 
Potentiation of tonic inhibition by THDOC was significantly altered in the presence of 
kinase activators (Kruskal-Wallis test, H = 16.04 P < 0.01 for drug). Specifically, post-hoc 
analysis revealed that PMA significantly attenuated the effects of THDOC increasing the 
tonic inhibition (19.5 ± 3.3 pA, n = 16, P < 0.001 vs. control). Similarly, forskolin treatment 
resulted in significantly smaller drop in holding current (28.9 ± 4.3 pA, P < 0.05, n = 28). 
7,8-DHF also resulted in similar change with holding current dropping only by 30.6 ± 7.3 
pA (P < 0.05, n = 16). These results show that kinases suppress the potentiating effect of 
THDOC on tonic inhibition. 
Kinases alone may have shifted the holding current prior to THDOC application and 
occluded the further potentiation by THDOC. To test this, we compared the holding 
currents of the control and the three kinase treatments before application of THDOC. We 
found no significant difference between the control vs. the kinase treatments (P > 0.05), 
although the overall difference was significant (Kruskal-Wallis test, H = 12.47, P < 0.05). 
The control holding current was −115.7 ± 14.0 pA (n = 18). The holding current before 
THDOC application for PMA (n = 16), forskolin (n = 28), 7,8-DHF (n = 16) treatments 
were −158.2 ± 12.7, −119.1 ± 11.4, −164.4 ± 12.2, and 147.9 ± 20.3 pA respectively. The 





Figure 2.5 Analysis of tonic current using Gaussian fitting to all-point histogram.  
(A) Representative gap-free tracing of the effect of THDOC on holding current. All-point 
histograms were created from 10-15 s of the recording (binned at 1 pA) before and after 
THDOC application, indicated by red and blue boxes, respectively. (B) Gaussian curve 
was fitted to the portion of the histogram that is not skewed by mIPSCs. Tonic inhibition 
was calculated as the difference between the peak amplitude values from the Gaussian fit 







Figure 2.6 Kinases suppress THDOC mediated potentiation of tonic inhibition. 
Representative tracings of (A) THDOC, (B) PMA + THDOC, (C) Forskolin + THDOC, 
and (D) 7,8-DHF + THDOC. (E) THDOC causes large inward shift of holding current, but 
when THDOC was applied in the presence of PMA, forskolin, or DHF, the shift was 
significantly less. (*P < 0.05, ***P < 0.001) 




It is well established that neurosteroids modulate GABAA receptor function (Wang, 2011). 
Studies have shown that this modulatory effect of neurosteroids can be changed by kinases, 
but the interaction is complex and likely involves receptor subtype-, cell type- and/or cell 
state-dependent mechanisms (Belelli et al., 2002; Harney et al., 2003; Lambert et al., 2003; 
Kia et al., 2011; Adams et al., 2015). In this study, we systematically investigated how 
activators for different kinases (PKA, PKC, and TrkB) modulate effects of the neurosteroid 
THDOC on mIPSC kinetics and tonic holding currents. We found that in general, kinases 
only have mild (or no) effect on THDOC modulation of mIPSCs while they greatly 
suppressed THDOC modulation of tonic inhibition. 
 Effect of THDOC on mIPSC 
We found that THDOC greatly potentiates mIPSCs as previously reported for pyramidal 
neurons in the rat piriform cortex (Kia et al., 2011). We observed that THDOC shortened 
τ1 and prolonged τ2. These effects are due to enhanced desensitization of GABAA receptor 
by THDOC (Zhu & Vicini, 1997). GABAA receptor desensitization occurs when the 
receptor closes while still bound to GABA, and it has been shown that changes in 
desensitization can alter the kinetics of IPSCs, mainly amplitude and decay (Dominguez-
Perrot et al., 1996; Jones & Westbrook, 1996). When desensitization is enhanced, the 
probability of GABA-bound receptors to close increases. The initial phase of decay (τ1) 
becomes faster as receptors close rapidly and go into desensitized state after binding GABA 
molecules instead of opening. Thus, as less channels are open upon binding of GABA, the 
peak amplitude is smaller.  
The longer τ2 could be a result of enhanced desensitization. When receptors enter the 
desensitized state, they can remain closed for tens or hundreds of milliseconds while still 
bound to GABA, and these receptors can open again (Jones & Westbrook, 1995; Zhu & 
Vicini, 1997). This results in a longer binding of GABA to its receptor and thus a prolonged 
decay of IPSCs. This has been predicted by our model of GABAA receptor IPSC kinetics 
(Dominguez-Perrot et al., 1996). Based on the change in mIPSC kinetics, we speculate that 
in the primary cortical neuron culture, THDOC increases mIPSC charge transfer by 
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increasing desensitization of GABAA receptor, similar to other neuronal preparations/cell 
types (Jones & Westbrook, 1995, 1996; Dominguez-Perrot et al., 1996; Zhu & Vicini, 
1997).  
 Effect of PMA on THDOC modulation of mIPSC 
We showed that PKC activation by PMA did not alter the modulatory effect of THDOC 
on mIPSCs. This was in contrast to our previous study on pyramidal cells of layer II 
piriform cortex where we found that PKC phosphorylation suppressed the effect of 
THDOC and resulted in significantly less charge transferred compared to untreated control 
(Kia et al., 2011). However, similar to our findings, Harney et al. (2003) reported that PKC 
activation by PMA failed to produce any effect on neurosteroid modulation of CA1 neuron 
mIPSCs. This discrepancy is perhaps due to variability in subunit composition of GABAA 
receptors in the different brain regions. Layer II piriform cortex has high abundance of β2 
subunits where as CA1 pyramidal cells show high β1 and β3 mRNA expressions (Wisden 
et al., 1992; Fritschy & Mohler, 1995; Kia et al., 2011). We used pyramidal cells cultured 
from the neocortex, and previous studies have reported that they show similar GABAA 
receptor subunit expression to adult cortex (Poulter et al., 1997; Hutcheon et al., 2000). Rat 
cortex shows moderate expression of both β2 and β3 (Laurie et al., 1992; Wisden et al., 
1992; Fritschy & Mohler, 1995), so phosphorylation of these receptors with different β 
subunits may be why we did not see any effect of PMA on THDOC modulation. 
 Effect of forskolin on THDOC modulation of mIPSC 
Activation of PKA by forskolin resulted in small changes to THDOC modulation of mIPSC 
amplitude and τ1. There was small but significant increase in amplitude when THDOC was 
applied, where without PKA activation, there was no change. τ1 was unaltered by THDOC, 
which in control was significantly shortened. These changes suggest that phosphorylation 
by PKA negatively affects desensitization of GABAA receptor by THDOC. As less 
receptors enter desensitization state, more receptors initially open upon binding of GABA. 
This would result in greater amplitude. However, the overall effect of THDOC was similar 
to control. There was no difference in its effect on τ2, which is the main effect of THDOC, 
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and thus the charge transfer. To the best of our knowledge, this is the first report of the 
effect of PKA activation on THDOC modulation of spontaneous mIPSCs.  
 Effect of 7,8-DHF on THDOC modulation of mIPSC 
THDOC application followed by TrkB activation using 7,8-DHF resulted in slight increase 
in mIPSC amplitude, with other parameters showing similar results to untreated cells. Like 
PKA activation, TrkB activation perhaps seems to negatively affect desensitization of 
GABAA receptor caused by THDOC, but the increase in amplitude did not result in any 
significant change to the overall charge transfer or the time course of the mIPSCs. Previous 
studies have shown that TrkB is able to activate PKC phosphorylation (Jovanovic et al., 
2004). However, while PKC activation had no effect on THDOC modulation, TrkB 
activation resulted in significant increase in amplitude. The increase in amplitude may be 
due to phosphorylation of γ2 subunit at Y365/367, which have been shown to enhance 
efficacy of synaptic inhibition (Vithlani et al., 2013).  Our study is the first to look at the 
effect of TrkB activation on THDOC modulation of mIPSCs.  
 Effect of kinases on THDOC modulation of tonic inhibition 
We found that application of THDOC caused a rapid inward shift in holding current 
peaking by 5 min. This potentiating effect of THDOC on tonic inhibition is consistent with 
previous studies (Stell et al., 2003; Kia et al., 2011). However, with all 3 kinases tested 
(PKC, PKA, and TrkB), the potentiating effect by THDOC was much less, showing that 
kinases greatly suppress the effect of THDOC on tonic inhibition. A recent study by 
Parakala et al. (2019) showed that neurosteroids have metabotropic effects, where they 
alter phosphorylation of GABAA receptors via membrane progesterone receptors. 
Importantly, the same study demonstrated that the metabotropic effects were slow acting 
(not evident within 5 min) but became effective and sustained after prolonged (15 min) 
application followed by 30-50 min wash (Parakala et al., 2019). We saw that the effect of 
THDOC appeared within minutes of application and reach peak effect by ~ 5 min. Thus, 
we conclude that our results of rapid THDOC actions are primarily attributable to the 
direct, allosteric effects of THDOC on GABAA receptors.   
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Our findings of kinases suppressing potentiation of tonic inhibition by neurosteroid are in 
line with previous reports. Kia et al. (2011) found that PKC activation resulted in 
suppression of THDOC potentiation of tonic inhibition in pyramidal cells of rat piriform 
cortex. The infusion of PKA to rat thalamocortical cells also showed a large decrease in 
tonic inhibition (Connelly et al., 2013). Our study is the first to report the effect of TrkB 
on neurosteroid modulation of tonic inhibition.  
The suppressing effect of kinases may be due to phosphorylation of δ subunit, which 
mediate tonic inhibition (Wei et al., 2003; Kia et al., 2011). δ subunits are expressed in the 
neocortex and have consensus sequences for phosphorylation similar to those found in 
other GABA subunits (Shivers et al., 1989). Previous studies showed that PKC-δ 
specifically targets δ subunit-containing GABAA receptors (Choi et al., 2008; Gonzalez et 
al., 2012). However, further studies are warranted to understand what specific site might 
be phosphorylated by which kinase, and how they modulate THDOC actions.    
The effects of THDOC on tonic inhibition have been reported to be heterogeneous to cell 
types and the state of the brain studies with some studies showing no effects while others 
showed potentiation (Porcello et al., 2003; Stell et al., 2003; Belelli & Lambert, 2005; 
Farrant & Nusser, 2005; Kia et al., 2011). Our finding that various types of phosphorylation 
suppressed THDOC modulation of tonic inhibition offer one plausible explanation for the 
heterogeneity: differing phosphorylation states of the extrasynaptic receptors control cell 
type- and state-dependent actions of THDOC.  
 Conclusion 
In the present study, we systematically examined the effects of three different kinase 
activators on THDOC modulation of phasic and tonic inhibition mediated by GABAA 
receptors. Overall, our data show that kinases differentially modulate effects of THDOC 
on phasic and tonic inhibition. The effects of kinase activation on THDOC-mediated 
modulation of phasic mIPSC were very subtle with charge transfer and the time course 
mostly unaffected. However, kinases greatly suppressed potentiation of tonic inhibition by 
THDOC. This results in shift in balance of tonic and phasic inhibition. In the presence of 
kinases, the effect of THDOC is mostly mediated through phasic IPSC. In some regions of 
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the brain, neurosteroids are ineffective at potentiating IPSCs, especially at low 
concentrations (Harney et al., 2003; Stell et al., 2003). In these regions, phosphorylation of 
extrasynaptic receptors might eliminate the effect of THDOC entirely. Loss of neurosteroid 
modulation can have important implications in development of the CNS and neurological 
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Chapter 3  
3 Suppression of GABAA receptor currents by the 
neurosteroid pregnenolone sulfate is not modulated by 
kinase activity 
 Introduction 
γ-aminobutyric acid type A (GABAA) receptors are ligand-gated ion channels that mediate 
inhibition in the brain. The synaptic GABAA receptors mediate phasic inhibition via 
inhibitory postsynaptic currents (IPSCs) (Whiting et al., 1999). There are also 
extrasynaptic receptors containing δ subunit that mediate tonic inhibition, which exerts 
persistent inhibition that controls the excitability of neurons (Farrant & Nusser, 2005). Both 
IPSCs and tonic inhibition by GABAA receptors are known to be modulated by 
neurosteroids (Scholfield, 1980; Majewska et al., 1986, 1988; Porcello et al., 2003; Stell et 
al., 2003). 
Neurosteroids are metabolites of sex and stress hormones known to alter neuronal 
excitability (Barker et al., 1987; Majewska et al., 1988). There are two types of 
neurosteroids; inhibitory neurosteroids that potentiate GABAergic transmission, and 
excitatory neurosteroids that suppress GABAergic transmission and/or enhance 
glutamatergic activity. Inhibitory neurosteroids have been previously shown to enhance 
IPSC by slowing the decay (Zhu & Vicini, 1997; Cooper et al., 1999; Kia et al., 2011). 
They can also potentiate tonic inhibition by increasing the open duration of extrasynaptic 
receptors (Wohlfarth et al., 2002). Neurosteroids are thought to play a role in many 
neurological and psychiatric disorders, including epilepsy, mood disorders, and anxiety 
due to their ability to modulate GABAA receptor function (Kokate et al., 1999; Reddy, 
2003; Mann & Mody, 2009; Brickley & Mody, 2012).  
Pregnenolone sulfate (PregS) is an excitatory neurosteroid that allosterically suppress 
GABAA receptor currents. Past studies have shown that PregS reduces peak IPSC 
amplitude and accelerates the decay (Poisbeau et al., 1997), greatly reducing charge 
transferred (Cl−) and thus suppressing GABAA receptor mediated IPSCs. As a result, it has 
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been shown to be anxiogenic and proconvulsive, as well as having memory enhancing 
effects (Kokate et al., 1999; Reddy, 2010a).  
The effects of neurosteroids can be modulated by protein kinase activity and 
phosphorylation of GABAA receptors (Moss et al., 1992; Harney et al., 2003; Kia et al., 
2011; Bright and Smart, 2013). For example, our previous investigations have shown that 
the inhibitory effect of neurosteroid tetrahydrodeoxycorticosterone (THDOC) is greatly 
diminished by PKC phosphorylation in epileptic rats (Kia et al., 2011). However, past 
studies have focused on the effects of inhibitory neurosteroids like THDOC. As such, very 
little is known whether protein kinases can alter the effects of excitatory neurosteroids on 
GABAergic IPSCs and tonic inhibition.  
Neurosteroids can affect memory, anxiety, mood disorders, epilepsy, behaviour, etc. 
(Kokate et al., 1999; Reddy, 2010a; Carver & Reddy, 2013). As such, understanding how 
they are modulated is vital in comprehension of CNS physiology and pathophysiology of 
neurological and psychiatric disorders. To the best of our knowledge, there has not been 
any studies that investigated the effect of kinase activation on PregS-mediated modulation 
of spontaneous GABAergic currents and, only a single study has been conducted regarding 
how kinase activation affects PregS effects on GABA-evoked current, looking at protein 
kinase C (PKC) activation in recombinant xenopus oocyte (Leidenheimer & Chapell, 
1997).  
Thus, the present study investigated kinase modulation of PregS effect on GABAA receptor 
currents. We studied the effects of PKC, protein kinase A (PKA), tyrosine receptor kinase 
B (TrkB) activators on PregS-mediated modulation of GABAA receptor mIPSCs and tonic 
currents in rat cortical pyramidal cells. 
 Materials and Methods 
All experiments were performed in accordance with the guidelines of Canadian Council on 




 Primary neuronal culture 
Pups from pregnant Sprague-Dawley rats (Charles River Laboratories, Quebec, Canada) 
were used to make primary neuronal culture. The pregnant rats were singly housed with ad 
libitum access to food and water under 12-hour light/dark cycle. The pregnant rats 
(embryonic day 18) were anesthetized by isoflurane and sacrificed by cervical dislocation 
to quickly isolate the embryos. Minimum of 5 different pregnant rats were used per 
treatment group. The embryos were then decapitated to isolate portions of developing 
cortex. The isolated brain portions were mechanically dissociated and plated in Neurobasal 
media with B-27 supplement and 2 mM L-glutamine (21103-049, 17504-044, Gibco, 
ThermoFisher Scientific, Waltham, MA, USA). Isolated cells were plated at a density of 1 
million cells/mL on Nunc 35-mm cell culture dish (1256590, ThermoFisher Scientific) 
treated with poly-D-lysine (P6407, Sigma-Aldrich, St. Louis, Mo, USA). The plated cells 
were incubated for minimum of 14 days for maturation. Media change occurred 3 times a 
week. 
 Solutions 
Electrophysiological recordings were conducted in external solution containing: 140 mM 
NaCl, 10 mM HEPES, 4.5 mM KCl, 0.5 mM CaCl2, 4 mM MgCl2, and 15 mM D-glucose 
(300-310 mOsm, pH 7.3). To isolate for mIPSCs, action potentials and glutamatergic 
transmissions (AMPA/kainite and NMDA) were blocked with 20 μM DL-2-amino-5-
phosphonopentanoic acid (DL-AP5; 0105, Tocris Bioscience, Bristol, UK), 20 μM 6-7-
dinitroquinoxaline-2,3-dione (DNQX; D0540, Sigma-Aldrich), and 200 nM tetrodotoxin 
(T-550, Alomone Labs, Jerusalem, Israel). The electrode solution consisted of: 145 mM 
CsCl, 0.3 mM CaCl2, 3 mM Na2EDTA, 10 mM HEPES, and 1 mM MgATP (295-305 
mOsm, pH 7.2–7.3). PregS (5376, Tocris Bioscience) was dissolved in DMSO at 100 mM 
and diluted to final concentration of 10 μM in external solution. Kinases that have been 
identified to phosphorylate GABAA receptors, and thus investigated are PKA, PKC, and 
TrkB. PKA was activated using 20 µM forskolin (F3917, Sigma-Aldrich), via activation 
of adenylyl cyclase. PKC was activated by 100 nM phorbol 12-myristate 13-acetate (PMA; 
1201, Tocris Bioscience), and TrkB was activated by 20 µM 7,8-dihydroxyflavone (7,8-
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DHF; 3826, Tocris Bioscience). Forskolin and PMA were applied intracellularly, and 7,8-
DHF was applied in the bath.  
 Electrophysiology and analysis 
Whole-cell voltage clamp recordings were obtained from morphologically identified 
pyramidal cells clamped at −60 mV. Recordings were performed at room temperature (22-
25 °C). Recordings were made with an Axopatch 200B amplifier (Molecular Devices, San 
Jose, CA, USA). The recordings were digitized by Digidata 1550 Digitizer controlled by 
pCLAMP 10 software suite (Molecular Devices) at 10 kHz (low-pass filtered at 2 kHz). 
The electrode resistance was between 5 and 10 MΩ. Series resistance was < 20 MΩ with 
70–80% compensation. Analysis of spontaneous mIPSCs was done using Clampfit 10.5 
(Molecular Devices). To minimize dendritically filtered events, all events that were 
analyzed had rise time < 2.5 ms. Each recording was averaged from minimum of 20 mIPSC 
traces. 
IPSC parameters that were analyzed are amplitude, decay constants (τ), fractional 
amplitude contribution, and the amount of charge transferred. The decay of GABAA 
receptor mIPSCs are often biphasic (Verdoorn, 1994; Ing & Poulter, 2007; Kia et al., 2011), 
and the mIPSCs we obtained were best fitted with biphasic exponential curve. The first 
component of decay (τ1) is fast, and the second component is slow (τ2). The decay curves 
of mIPSCs were fitted with standard exponential function found in Clampfit 10.5: 
∑ /  (Otis & Mody, 1992; Zhu & Vicini, 1997; Hutcheon et al., 2000). 
Fractional amplitude contribution was calculated for τ1 (a1) as A1/(A1 + A2) where A1 is the 
amplitude of τ1 and A2 is the amplitude of τ2 (Mørkve & Hartveit, 2009). a1 represents how 
much τ1 accounts for the whole of decay. For example, a1 of 0.3 means that τ1 is responsible 
for the decay of 30% of the amplitude, whereas τ2 is responsible for remaining 70%. Charge 
transfer was calculated as area under the curve of mIPSC.  
Tonic currents were calculated from Gaussian fit to all-point histograms of amplitude. 
Histograms were created from 10-15 s of data from gap free recordings (bin width 1 pA) 
before and after THDOC application. Gaussian curve was fitted to the portion of all-point 
histogram not skewed by mIPSCs (Glykys & Mody, 2007). The difference between the 
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peak amplitude values from the Gaussian fit pre- and post-THDOC applications were used 
to calculate the change in tonic inhibition. 
 Statistical analysis 
D'Agostino & Pearson test was performed to assess the normality of data. The changes in 
mIPSC kinetics (amplitude, time constants, charge transfer) were evaluated using a paired 
t-test for parametric data and Wilcoxon matched-pairs signed rank test for non-parametric 
data on Prism 8.4.2 (GraphPad Software Inc., San Diego, CA, USA). For comparison of 
change in tonic inhibition, one-way ANOVA, followed by Tukey’s multiple comparisons 
test was used for parametric data and Kruskal-Wallis test, followed by Dunn’s multiple 
comparisons test was used for non-parametric data. The significance was set at P < 0.05 
for all statistical tests. All data are expressed as mean ± SEM. 
 Results 
 Kinases do not alter PregS modulation of GABAA receptor 
mIPSCs 
PregS has been previously shown to negatively modulate GABAergic currents (Majewska 
et al., 1988; Le Foll et al., 1997; Leidenheimer & Chapell, 1997), but as effects of 
neurosteroids can vary depending on cell type/preparation (Jussofie, 1993; Cooper et al., 
1999), we first investigated the effect of PregS on mIPSCs from pyramidal cells of cultured 
rat cortical neurons. We applied 10 μM PregS in the bath and analyzed mIPSCs 5-10 min 
after PregS application. This concentration was chosen based on previous studies reporting 
the modulatory effect of PregS on GABAA receptor IPSCs (Zhu et al., 1996; Le Foll et al., 
1997; Park-Chung et al., 1999; Shen et al., 2000).We found that PregS (10 μM) potently 
suppressed mIPSCs (Figure 3.1) as seen in large decrease in charge transfer (−2.90 ± 0.45 
vs 1.00 ± 0.25 pC, P < 0.001, n = 11). PregS also significantly decreased the peak amplitude 
from −55.8 ± 5.6 pA to −30.6 ± 3.5 pA (P < 0.001). The decay kinetics of mIPSCs were 
best fitted with biexponential curve, and PregS accelerated both τ1 (12.6 ± 2.1 vs 7.3 ± 1.8 
ms, P < 0.01) and τ2 (63.9 ± 6.5 vs 39.9 ± 4.1 ms, P < 0.0001). The fractional amplitude 
contribution of fast decay a1 (see Materials and Methods for detail) did not change with 
PregS treatment (0.26 ± 0.03 vs 0.24 ± 0.02, P > 0.05). 
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Next, we investigated the effects of PKC activation by PMA (20 μM) on PregS-mediated 
modulation of mIPSCs. PKC has been shown to phosphorylate β1-3 and γ2 subunits 
(Kellenberger et al., 1992; Krishek et al., 1994; Brandon et al., 1999). Neurons were treated 
with PMA for at least 10 min. PMA did not alter PregS modulation and the effects were 
similar to that of PregS without kinase activation (Figure 3.2) with large decrease in charge 
transfer (−3.20 ± 0.23 pC vs −1.20 ± 0.17 pC, P < 0.0001).  There was significant decrease 
in amplitude (−61.9 ± 4.3 vs −36.0 ± 3.1 pA, P < 0.0001, n = 15).  and acceleration of both 
τ1 (12.8 ± 1.3 vs 5.2 ± 1.3 ms, P < 0.0001) and τ2 (63.5 ± 2.5 vs 38.4 ± 2.7 ms, P < 0.0001). 
Lastly, a1 did not change with the treatment (0.26 ± 0.03 vs 0.23 ± 0.02, P > 0.05). 
Next, we looked at the effect of PKA activator Forskolin (20 μM). Forskolin did not change 
PregS modulation of mIPSCs (Figure 3.3). PKA is known to phosphorylate β2 and β3 
subunits (Moss et al., 1992; McDonald et al., 1998). The effect of PregS in forskolin treated 
cells were similar to non-kinase control with decreased charge transfer (−2.55 ± 0.25 vs 
0.97 ± 0.06 pC, P < 0.0001, n = 17), smaller peak amplitude (−51.0 ± 3.2 vs −28.8 ± 1.6 
mV P < 0.0001), faster τ1 (11.0 ± 0.8 vs 5.3 ± 0.7 ms, P < 0.0001) and τ2 (61.0 ± 3.0 vs 
40.8 ± 1.9 ms, P < 0.0001), and no change to a1 (0.27 ± 0.03 vs 0.26 ± 0.03, P > 0.05). 
Next, we investigated the effect of the TrkB agonist 7,8-DHF on PregS modulation of 
mIPSCs (Figure 3.4). TrkB is a receptor for brain-derived neurotrophic factor (BDNF) and 
can phosphorylate β3 and γ2 subunits (Jovanovic et al., 2004; Nakamura et al., 2015b). 
Unlike PMA and forskolin PregS significantly increased a1 in 7,8-DHF treated cells (0.21 
± 0.02 vs 0.26 ± 0.01, P < 0.05). However, all other parameters were similar to control and 
other kinase treatment. There was a large decrease in charge transfer similar to control 
(−2.58 ± 0.27 vs −1.22 ± 0.12 pC, P < 0.0001, n = 14). PregS decreased the amplitude 
(−50.6 ± 3.8 vs −36.6 ± 3.5 mV, P < 0.001), accelerated τ1 (6.6 ± 0.8 vs 4.7 ± 0.4 ms, P < 
0.01) and τ2 (57.8 ± 3.2 vs 42.0 ± 3.0ms, P < 0.0001).. 
To compare the magnitude of inhibition between the treatments, % inhibition was 
calculated for all mIPSC parameters (Table 3.1). There was no significant difference 
between control compared to the 3 kinase treatments. However, for 7,8-DHF, there was a 
trend in amplitude (P = 0.054) and charge transfer (0.062), where 7,8-DHF treated cells 
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showed less inhibition than control. As 7,8-DHF itself may have had effect on mIPSC 
kinetics that could occlude the effect of PregS, we also compared the mIPSC parameters 
before PregS treatment (Table 3.2). 7,8-DHF treated cells showed significantly faster τ1 
compared to control (12.6 ± 2.1 vs. 6.6 ± 0.8 ms, P < 0.05). This may have had an impact 
on the effect of PregS.   
In summary, PregS significantly suppressed mIPSCs by reducing charge transfer via 
decreasing amplitude and accelerating the decay. PKC, PKA, and TrkB did not alter the 
effect of PregS on mIPSC. However, while it was not significant, 7,8-DHF had a tendency 






Figure 3.1 PregS suppressed GABAA receptor mediated mIPSCs by reducing the 
amplitude and decay constants.  
(A) Representative tracings of control mIPSC (B) Average amplitude of mIPSCs was 
significantly lower when PregS was applied. (C & D) PregsS accelerated both the fast 
decay constant (τ1) and slow decay constant (τ2). (E) The fractional amplitude contribution 
of τ1 (a1) did not change when treated with PregS. (F) Amount of charge transferred 







Figure 3.2 PMA did not modulate the effect of PregS on mIPSCs.  
(A) Representative tracings of mIPSC. (B) Average amplitude of mIPSCs significantly 
decreased when PregS was applied. (C & D) PregsS accelerated both the fast decay 
constant (τ1) and slow decay constant (τ2). E) The fractional amplitude contribution of τ1 
(a1) remained unaffected when treated with PregS. (C) Amount of charge transferred 






Figure 3.3 Forskolin did not modulate the effect of PregS on mIPSCs.  
(A) Representative tracings of mIPSC. (B) Average amplitude of mIPSCs significantly 
decreased when PregS was applied. (C & D) PregsS accelerated both the fast decay 
constant (τ1) and slow decay constant (τ2). E) The fractional amplitude contribution of τ1 
(a1) remained unaffected when treated with PregS. (C) Amount of charge transferred 







Figure 3.4 PregS significantly increased a1 when applied after 7,8-DHF treatment.  
(A) Representative tracings of mIPSC. (B) Average amplitude of mIPSCs significantly 
decreased when PregS was applied (C & D) PregsS accelerated both the fast decay constant 
(τ1) and slow decay constant (τ2). (E) The fractional amplitude contribution of τ1 (a1) 
significantly increased when treated with PregS. (F) Amount of charge transferred 
decreased significantly with the application of PregS. (*P < 0.05, **P < 0.01, ***P < 0.001, 




Table 3.1 Average percent inhibition by PregS on mIPSC kinetics 
 




(n = 11) 
42.6 ± 16.8 41.5 ± 8.7 36.4 ± 3.4 −33.3 ± 21.9 62.9 ± 5.4 
PMA 
(n = 15) 
41.1 ± 4.1 62.6 ± 5.8 39.7 ± 3.5 −2.6 ± 15.6 62.7 ± 4.6 
Forskolin 
(n = 17) 
42.1 ± 3.2 50.9 ± 4.4 32.3 ± 2.7 −1.1 ± 10.2 59.2 ± 3.0 
7,8-DHF 
(n = 14) 
27.7 ± 3.0 
(P = 0.054) 
19.7 ± 7.3 
(P = 0.12) 
27.1 ± 3.5 −30.4 ± 11.6 
51.7 ± 2.7 
(P = 0.06) 
















(n = 11) 
−55.8 ± 5.6 12.6 ± 2.1 63.9 ± 6.5 0.30 ± 0.04 −2.90 ± 0.45 
PMA  
(n = 15) 
−61.9 ± 4.3 12.8 ± 1.3 63.5 ± 2.5 0.26 ± 0.03 −3.20 ± 0.23 
Forskolin  
(n = 17) 
−51.0 ± 3.2 11.0 ± 0.8 61.0 ± 2.9 0.27 ± 0.03 −2.55 ± 0.25 
7,8-DHF  
(n = 14) 
−50.6 ± 3.8 6.6 ± 0.8* 57.8 ± 3.2 0.21 ± 0.02 −2.58 ± 0.27 




 PregS does not modulate tonic inhibition 
In addition to phasic GABAA receptor currents, neurosteroids such as THDOC and 
allopregnenolone have been shown to modulates tonic GABAA receptor currents by 
targeting extrasynaptic receptors (Stell et al. 2003; Carver and Reddy 2013). Whether 
PregS affects tonic GABAA receptor currents, and if kinase activities modulate PregS 
effects on tonic GABAA receptor currents remain unknown. Changes in tonic inhibition 
was calculated as the difference between the holding current before and after 5 min 10 μM 
PregS application. The holding currents were calculated from all-point histograms from 
10-15 s of gap free recordings before and after THDOC application by performing 
Gaussian fits.  
Application of PregS resulted in no change in tonic inhibition with change in holding 
current of 7.18 ± 5.96 pA (n = 11, Figure 3.5). The effect of PregS did not change with any 
of the three kinases tested (Kruskal-Wallis test, H = 3.46, P > 0.05). PKC activation by 
PMA resulted in change in holding current of 4.06 ± 3.12 pA (n = 16), PKA activation by 
forskolin resulted in change of 9.79 ± 3.41 pA (n = 17), and TrkB activation by 7,8-DHF 
resulted in change of −4.34 ± 7.25 pA (n = 16).  
As kinase activation by itself may have shifted holding current before PregS application 
and occlude its (lack of) effect, we compared the holding currents of the control and the 
three kinases prior to PregS application. We found that the holding currents before PregS 
application were not significantly different (one-way ANOVA, F3,56 = 2.04, P > 0.05). The 
holding current for control was −136.0 ± 12.2 pA. The holding currents for PMA, forskolin, 







Figure 3.5 PregS does not alter tonic inhibition.  
Representative tracings of (A) PregS, (B) PMA + PregS, (C) Forskolin + PregS, and (D) 
7,8-DHF + PregS show no change in tonic curernt. (B) There was no significant difference 





Many previous studies have shown that the effects of inhibitory neurosteroids on GABAA 
receptor can be modulated by kinase activation (Belelli et al., 2002; Harney et al., 2003; 
Kia et al., 2011). However, very little is known about kinases’ effect on the regulation of 
GABAA receptor activity by excitatory neurosteroids like PregS. We found that activation 
of three major kinases (PKC, PKA, and TrkB) does not alter the effects of PregS on 
mIPSCs. We also found that PregS does not modulate tonic inhibition, and kinase 
activation does not alter its lack of effect. 
 Effect of kinases on PregS-mediated modulation of mIPSC 
We found the PregS greatly suppress mIPSCs of cultured cortical pyramidal cells. We saw 
that PregS reduced the peak amplitude and accelerated the decay of mIPSCs. Our findings 
were in agreement with previous reports on evoked IPSCs (Le Foll et al., 1997; 
Leidenheimer & Chapell, 1997; Shen et al., 2000). All 3 kinases that were tested (PKC, 
PKA, and TrkB) did not alter the overall suppressing effect of PregS on mIPSCs. Similar 
to our findings, Leidenheimer and Chapell (1997) found that PKC activation by PMA did 
not alter the effect of PregS on recombinant GABAA receptors. This lack of kinase 
modulation is in contrast to what occurs with inhibitory neurosteroids, such as THDOC, 
where kinase activation alters neurosteroid modulation of various mIPSC kinetics 
(Leidenheimer & Chapell, 1997; Kia et al., 2011; Adams et al., 2015). This difference is 
perhaps because sulfated neurosteroids bind to different site from inhibitory neurosteroids. 
While M1 domain of α subunit is critical for binding of THDOC (Akk et al., 2008), a recent 
study by Laverty et al. (2017) found that PregS interacts with M3 and M4 domains. 
Because PregS binds to a discrete site away from THDOC, it is perhaps why 
phosphorylation does not alter its effect.  
Although not significant, 7,8-DHF treatment resulted in smaller decrease in amplitude and 
charge transfer. Further analysis revealed that 7,8-DHF treated cells showed faster decay 
(τ1) compared to control before THDOC application. This may have occluded the effect of 
PregS and may explain the trend. Past studies have shown that TrkB downregulates 
GABAA receptor IPSCs. Activation of TrkB by BDNF resulted in attenuated GABAA 
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receptor-mediated currents in mouse cerebellar granule cell culture (Cheng & Yeh, 2003), 
and BDNF knock-out results in higher amplitude IPSCs in mice superior colliculus neurons 
(Henneberger et al., 2002).  
PregS has been shown to be a positive allosteric modulator of the N-methyl-D-aspartate 
(NMDA) receptor (Wu et al., 1991; Bowlby, 1993; Ceccon et al., 2001), and the 
potentiation of NMDA receptor current by PregS is dependent on PKA activation (Petrovic 
et al., 2009). Thus, we speculate that PregS acts to broadly dampen inhibition by GABAA 
receptors but has more cell-/region-specific effects on modulating excitatory currents, 
controlled by kinase activity.  
 Effect of PregS on tonic inhibition 
We found that PregS did not alter the holding current and thus, not alter tonic inhibition by 
GABAA receptors. Kinase activation (PKC, PKA, and TrkB) did not change the lack of 
effect by PregS on tonic current. This lack of effect by PregS is consistent with previous 
report on GABA-elicited currents in transfected HEK 293 cells that showed δ-subunit 
suppresses PregS efficacy (Zhu & Vicini, 1997).  
However, the mechanism behind the difference in PregS effect between phasic (IPSC) and 
tonic current is still elusive. As past studies have focused on GABAA receptor currents 
elicited by brief, high concentration of GABA (Majewska et al., 1988; Shen et al., 2000; 
Strömberg et al., 2009; Seljeset et al., 2018), very little is known about PregS effect on low 
levels of persistent GABA like those seen in extracellular receptors mediating tonic 
inhibition. However, we speculate that this difference may be due to different α subunit 
compositions. In the cortex, synaptic receptors with γ subunit typically contain α1 and α2 
subunits, but extrasynaptic receptors with δ subunit contain α4 subunit (McKernan & 
Whiting, 1996; Whiting et al., 1999; Olsen & Sieghart, 2009). This difference may have 
resulted in the differing effects of PregS on phasic and tonic GABAergic currents. 
 Conclusion 
In the present study, we examined the effects of activating three kinases, PKC, PKA, and 
TrkB, on PregS-mediated modulation of GABAA receptor mediated phasic and tonic 
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currents. We found that PKA and PKC do not modulate the effect of PregS on mIPSCs, 
whereas TrkB may diminish the effect of PregS on mIPSCs. We also showed that PregS, 
with or without kinase activators, does not modulate tonic inhibition. Further studies are 
warranted to investigate the mechanism behind the difference of PregS effect between 
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Chapter 4  
4 Kinase regulation of neurosteroid activity in the rat 
piriform cortex 
 Introduction 
Neurosteroids, metabolites of steroid hormones, modulate GABAA receptor mediated 
inhibition. Inhibitory neurosteroids, such as tetrahydrodeoxycorticosterone (THDOC; 
metabolite of deoxycorticosterone) have been shown to potentiate GABAergic inhibition 
(Majewska et al., 1986; Stell et al., 2003; Schwabe et al., 2005). Neurosteroids typically 
enhance synaptic inhibition by prolonging the time course/decay of the inhibitory 
postsynaptic currents (IPSCs) (Fáncsik et al., 2000; Schwabe et al., 2005; Gavrilovici et 
al., 2006). Neurosteroids also potentiate tonic inhibition mediated by extrasynaptic 
receptors (Wohlfarth et al., 2002; Schwabe et al., 2005; Kia et al., 2011). The potentiating 
effect of neurosteroids on GABAA receptors has been shown to be modulated by 
intracellular kinase activity, though a diverse effect is seen depending on GABAA receptor 
subtype compositions and/or cell type (Harney et al., 2003; Lambert et al., 2003; Kia et al., 
2011).  
Previously, we showed that the neurosteroid THDOC enhances GABAergic transmission 
in layer II pyramidal cells of the piriform cortex (PCtx) (Gavrilovici et al., 2006; Kia et al., 
2011), and PKC activation suppresses this effect (Kia et al., 2011). However, it remains 
unclear how THDOC affects the circuit level activities of the PCtx, due to its complexity 
and limited information on the interneurons involved. Furthermore, the effects of kinase 
modulation of neurosteroid activity on the circuit is unknown. 
The PCtx is a region of the olfactory cortex. It receives direct input from the lateral 
olfactory tract (LOT) and has dense connections to the amygdala, hypothalamus, and 
entorhinal cortex (Krettek and Price, 1978a, 1978b; Wakefield, 1980; Carlsen, Jørn de 
Olmos and Heimer, 1982), which are structures involved in epileptogenesis. As such, it is 
one of the most seizure susceptible regions of the brain and has been implicated in temporal 
lobe epilepsy (Löscher and Ebert, 1996; Vaughan and Jackson, 2014). PCtx is also 
extremely sensitive to kindling, a phenomenon where repeated stimulations/seizures result 
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in progressively more severe seizure response (McIntyre et al., 1999). In fact, PCtx has 
been shown to be more sensitive to kindling than the hippocampus and amygdala, areas 
widely known to be seizure prone (McIntyre et al., 1999; McIntyre & Gilby, 2008). Some 
studies have suggested that PCtx activation is required for kindling (Sato et al., 1988; 
Morimoto et al., 2004).  
Our laboratory has previously characterized a novel neural circuit involved in epilepsy that 
lies across PCtx and the dorsal endopiriform nucleus (DEn) (Birjandian et al., 2013). The 
PCtx circuit is a feed-forward disinhibitory loop that augments excitatory 
neurotransmission. Layer II of PCtx, densely populated with pyramidal cells, projects to 
DEn interneurons. In turn, the DEn interneurons innervate layer III PCtx interneurons. 
Layer III interneurons in turn innervate layer II pyramidal cells, forming a disinhibitory 
loop. The activation of layer II pyramidal cells (via stimulation of their apical dendrites in 
LOT) activates DEn interneurons, which then inhibit layer III interneurons. Due to this 
disinhibition, layer III interneurons can no longer attenuate layer II, resulting in prolonged 
circuit activity.  
In the present study, using voltage sensitive dye imaging (VSDI), we investigated the 
effect of the inhibitory neurosteroid THDOC on the activity of the PCtx circuit, and how 
it is modulated by PKC, protein kinase A (PKA), and tyrosine receptor kinase B (TrkB). 
All three kinases have been previously shown to modulate GABAA receptor function 
(Kittler & Moss, 2003). VSDI allows for simultaneous recording and visualization of 
neuronal activity of a large area of the brain and is particularly useful for studying circuit 
behaviour (Birjandian et al., 2013). 
 Materials and Methods 
All experiments were performed in accordance with the guidelines of Canadian Council on 
Animal Care and approved by the University of Western Ontario Animal Care Committee 
(AUP 2010-017, 2018-083). No animal has been excluded. No randomization was 




 Brain slice preparation 
Male Sprague Dawley rats (Charles River Laboratories, Quebec, Canada) weighing 200 to 
300 g were used in the experiments. Animals were housed individually with free access to food 
and water under 12-hour light and dark cycle. Animals were anaesthetized with ketamine-
medetomidine HCl combination and perfused with ice-cold artificial cerebrospinal fluid 
(ACSF) with choline ions replacing sodium ions. ACSF composition was as follows: 100 
mM choline Cl, 2.5 mM KCl, 1.2 mM NaH2PO4, 25 mM NaHCO3, 0.5 mM CaCl2, 7 mM 
MgCl2, 2.4 mM Na pyruvate, 1.3 mM ascorbate, and 20 mM D-glucose. After perfusion, 
the brain was rapidly removed, and the brain was sliced using Vibratome into 400-μm 
slices. The slices were incubated in 37˚C ACSF bath for 35 min and then in room 
temperature (22˚C) bath for 45 min. The ACSF during perfusion, slicing, and incubation 
was supplied with carbogen (95% O2 and 5% CO2 mixture). 
 Voltage sensitive dye staining and imaging 
After incubation, slices were incubated in the voltage sensitive dye Di-4-ANEPPS. Dye 
incubation solution consisted of 60 μM of dye stock, 500 μM of fetal bovine serum, and 
500 μM of bicarbonate ACSF.  Final dye concentration in the solution was 0.1 mg/mL. 
The bicarbonate ACSF was composed of 110 mM NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 
25 mM NaHCO3, 2.0 mM CaCl2, 2.0 mM MgCl2, and 20 mM D-glucose. The pH was 
between 7.3 and 7.4 and the osmolarity was 297 to 305 mOsm. After 30 min incubation in 
the dye solution, slices were washed with the bicarbonate ACSF to remove excess dye. 
Then, the slices were transferred to a recording chamber supplied with carbogen-bubbled 
32 °C bicarbonate ACSF. A platinum-iridium electrode with a tip diameter of 200-300 μm 
(MicroProbes, Gaithersburg, MD, USA)  was used to stimulate the LOT of the PCtx (Narla 
et al., 2016b).  
MiCAM ULTIMA complementary metal-oxide-semiconductor (CMOS) camera system 
(Brainvision Inc., Tokyo, Japan) was used to record the optical signals. CMOS camera was 
mounted on fixed-stage upright microscope (BX51WI, Olympus Corporation, Tokyo, 
Japan). Slices were illuminated using 100-W halogen lamp source passed through 
excitation filter (λ = 530 ± 10 nm). A long-pass emission filter (λ > 590 nm) collected the 
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fluorescent signals. Objective used in the experiments was 4× long working distance 
objective (NA = 0.28, Olympus Corporation). Obtained data was analyzed using 
BV_Analyzer (Brainvision Inc.) Detailed explanation of the analysis is described 
elsewhere (Birjandian et al., 2013). Change in fluorescence signal relative to the 
background (ΔF/F) was calculated for each frame of the recordings. As there was 
variability in response from slice to slice due to loading of the dye, all recordings were 
normalized by dividing all signals by response to the control 20 Hz stimuli. The stimulus 
frequencies tested were 10, 20, 40, 60, and 80 Hz.   
 Reagents 
Di-4-ANEPPS (D8064, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 100% 
ethanol (EtOH) at 22 mg/mL. THDOC (P2016, Sigma-Aldrich) was dissolved in 100% 
EtOH at 10 mM, and this stock was diluted to final concentration of 100 nM in the external 
solution (final EtOH 0.001%). Protein kinases that were investigated were PKA, PKC, and 
TrkB. PKA was activated by 20 µM forskolin via activation of adenylyl cyclase (F3917, 
Sigma-Aldrich), PKC by 100 nM phorbol 12-myristate 13-acetate (PMA; 1201, Tocris 
Bioscience, Bristol, UK), and TrkB by 20 µM 7,8-dihydroxyflavone (7,8-DHF; D5446, 
Sigma-Aldrich). All kinase activators and THDOC were applied in bath for minimum of 
10 min.  
 Statistical analysis 
All statistical analyses were done using Prism 8.4.2 (GraphPad Software Inc., San Diego, 
CA, USA). Comparison of all data was done using repeated-measures two-way analysis of 
variance (ANOVA), followed by Fisher’s least significance difference test. The 
significance was set at P < 0.05 for all statistical tests. All data are expressed as mean ± 
SEM. 
 Results 
 THDOC suppresses PCtx circuit activity 
Our laboratory has previously demonstrated the propagation of prolonged activation in the 
PCtx circuit following high-frequency electrical stimulation of LOT (Birjandian et al., 
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2013). First, we replicated our earlier finding using VSDI recording (Figure 4.1). 
Stimulation of LOT (20-80 Hz stimulus for 1 s) triggered prolonged responses with both 
excitatory and inhibitory responses in distinct layers of PCtx and DEn. Specifically, 
stimulation of LOT activated layer II within a few milliseconds. About 40-50 ms later, DEn 
was activated, followed by deactivation (reduced firing of interneurons) of layer III (~ 200 
ms later) as a result of reduction in action potential frequency of the interneurons in the 
layer (Birjandian et al., 2013). Based on the anatomy and cellular connections of the 
regions involved and the timing of the response to LOT stimulation, our interpretation of 
this sequence of activity changes is as follows: Layer II pyramidal cells activate DEn 
interneurons, which in turn inhibit layer III interneurons. This disinhibition of layer III 
interneurons, which loop back to send inhibitory inputs to layer II, means that the layer II 
pyramidal cells can no longer be attenuated, creating a disinhibitory circuit.  
Next, we studied the effects of neurosteroid on the stimulation-evoked activation of PCtx 
circuits. The signal intensity of the voltage sensitive dye changes in response to change in 
membrane potential. All recordings were normalized to the response to 20 Hz stimulus for 
control (untreated) recording to compensate potential slice-to-slice variability in dye 
loading. We observed that 100 nM THDOC reduced the activation of layer II and DEn and 
deactivation of layer III (Figure 4.2 A,B). In layer II (Figure 4.2 C), THDOC reduced 
activation of the layer (F1,55 = 15.13, P < 0.001, n = 12).  Activation of DEn was also 
reduced by THDOC (Figure 4.2 D; F1,55 = 21.41, P < 0.0001). The inhibition of layer III 
(deactivation) decreased with THDOC application (Figure 4.2 F; F1,55 = 17.15, P < 0.001). 
The effects of THDOC were seen with stimulation in γ frequency range (40-80 Hz), but 
not at lower frequencies (10-20 Hz). These data indicate that THDOC suppresses the 





Figure 4.1 Activation of PCtx visualized with voltage sensitive dye imaging (VSDI).  
(A) Snapshots from 10 s recording with PCtx stimulated at 80 Hz show PCtx circuit 
activity. Warm colours (red, yellow, and green) represent activation and cool colours (blue 
and purple) represent deactivation. (B) Waves on the right indicated by arrows show 
responses from the stimulation, with top wave showing activation of layer II, middle 







Figure 4.2 THDOC suppressed the activity of the PCtx circuit.  
(A) Representative voltage sensitize dye imaging shows activation of layer II PCtx and 
dorsal endopiriform nucleus (DEn) and deactivation of layer III PCtx in untreated control 
slice and (B) after 100 nM THDOC treatment. (C) Activation of layer II decreased 
significatly for 40, 60, and 80 Hz stimulation when treated with 100 nM THDOC. (D) 
Deactivation of Layer III decreased significantly at 40, 60, and 80 Hz. (E) Activation of 




Table 4.1 Effect of kinases and THDOC on PCtx circuit activity 
 Control PMA Forskolin 7,8-DHF 
No THDOC  ↓ NC NC 
+ THDOC ↓ NC/↑ NC NC 




 PMA suppresses PCtx circuit activity and the effect of THDOC 
Next, we tested the effects of PKC activation by 100 nM PMA and how that may change 
the suppressing effect of THDOC (Figure 4.3). Overall, PMA alone decreased the activity 
of the PCtx circuit, as previously demonstrated (Narla et al., 2015). Specifically, there was 
decreased activation of layer II (Figure 4.3D; F2,80 = 16.31, P < 0.0001, n = 9) and DEn 
(Figure 4.3 F; F2,80 = 29.41, P < 0.0001), and decreased deactivation of layer III (Figure 
4.3 E; F2,80 = 13.49, P < 0.0001).  All layers showed significant decrease in 
activation/deactivation at 40-80 Hz stimulation, and DEn also showed decreased activity 
at 20 Hz. Subsequent application of 100 nM THDOC did not alter the circuit activity in 
layer II, abolishing the suppressive effect of THDOC seen without kinase activation. 
However, THDOC caused slight increase in activity in DEn at 60 Hz (P < 0.05), and in 
layer III at 40 and 60 Hz (P < 0.05). These data show that PKC activation by PMA 







Figure 4.3 Activation of PKC by PMA suppressed the activity of the PCtx circuit and 
the effect of THDOC.  
(A-C) Representative voltage sensitive dye imaging of the PCtx at 80 Hz stimulation. (D) 
PMA significantly reduced the activation of Layer II at 40, 60, and 80 Hz. Subsequent 
THDOC administration did not significantly change the activity of layer II. (E) Layer III 
deactivation was significantly suppressed by PMA at 40, 60, and 80 Hz stimulation. 
Subsequent THDOC administration increased the deactivation of layer III at 40 and 60 Hz 
stimulation, but not at other frequencies. (F) The activation of DEn was significantly 
suppresed by PMA at 20, 40, 60, and 80 Hz. Subsquent THDOC application did not change 
the activity of DEn, excpet at 60 Hz stimulation, where it slightly increased the activation. 
(*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 for control vs. PMA; #P < 0.05, 
##P < 0.01, #### P < 0.0001 for control vs. PMA + THDOC; †P < 0.05, ††P < 0.01 for 




 Forskolin does not alter PCtx circuit activity, but abolishes 
THDOC effect 
Next, we investigated the effect of PKA, another major kinase that modulates GABAergic 
activities (Figure 4.4). The application of 20 μM forskolin (adenylyl cyclase activator) did 
not change the activation of layer II (Figure 4.4 D, F2,60 = 0.58, P > 0.05, n = 7),  DEn 
(Figure 4.4 F; F2,60 = 0.22, P > 0.05) and layer III (Figure 4.4 F; F2,60 = 0.03, P > 0.05). 
However, forskolin pre-exposure completely abolished the effects of THDOC (Figure 4.4, 
D-F), as the effect of forskolin alone vs forskolin + THDOC were not significantly different 
at all frequencies tested (P > 0.05). These data indicate that while the activation of PKA 







Figure 4.4 Activation of PKA by forskolin did not alter the activity of the PCtx circuit 
and suppressed the effect of THDOC.  
(A-C) Representative voltage sensitive dye imaging of the PCtx at 80 Hz stimulation. (D) 
Forskolin did not alter the activation of layer II at all frequencies tested, and subsequent 
application of THDOC also did not have any effect (E) Layer III deactivation was not 
altered by forskolin nor subsequent application of THDOC. (F) The activation of DEn was 




 DHF does not alter PCtx circuit activity, but abolishes THDOC 
effect 
Lastly, we examined the effect of 7,8-DHF, a TrkB agonist (Figure 4.5). Overall, 20 μM 
7,8-DHF did not alter the activity of the PCtx circuit, except for in layer II at 80 Hz, where 
7,8-DHF significantly decreased the activation (Figure 4.5 D, F2,60 = 5.86, P < 0.01, n = 
7). This is likely due to variability in slice conditions. Other stimulus frequencies (10, 20, 
40, and 60 Hz) did not show any significant change in response to 7,8-DHF. Layer III 
(Figure 4.5 E, F2,60 = 1.16, P > 0.05) and DEn (Figure 4.5 F, F2,60 = 1.44, P > 0.05) activities 
were not altered by 7,8-DHF. However, like other kinase activators, 7,8-DHF abolished 
the effect of THDOC (Figure 4.5 D-F). These data show that while 7,8-DHF by itself does 






Figure 4.5 Activation of TrkB by 7,8-DHF did not alter the activity of the PCtx circuit 
and suppressed the effect of THDOC.  
(A-C) Representative voltage sensitive dye imaging of the PCtx at 80 Hz stimulation. (D) 
7,8-DHF did not alter the activation of layer II except at 80Hz stimulation, where it reduced 
the activation. THDOC application that followed did not after the activity of layer II, except 
at 40 Hz where it was reduced significantly. (E) Layer III deactivation was not significantly 
altered by 7,8-DHF and THDOC. (F) DEn activation was not affected by 7,8-DHF and 
THODC (****P < 0.0001 for control vs. 7,8-DHF; ###P < 0.001 for control vs. 





Our laboratory has previously investigated the effects of PKC activation on the activity of 
neurosteroid THDOC in layer II pyramidal cells of the PCtx (Kia et al., 2011). More 
recently, we have characterized a novel feed-forward disinhibitory circuit involving the 
PCtx that may play a role in epilepsy (Birjandian et al., 2013). Despite its role in epilepsy, 
PCtx has not well been investigated compared to other structures (e.g. amygdala, 
hippocampus), and the activity of neurosteroids have never been documented in the PCtx 
circuit. As neurosteroids are currently being investigated as antiseizure medication 
(Chuang & Reddy, 2020), it is important that we understand how neurosteroid affect the 
activity of the PCtx circuit, and how it is modulated by kinase activation. Thus, in this 
study, we examined the activity of the neurosteroid THDOC and how 3 different kinases 
(PKC, PKA, and TrkB) alter its activity. We found that THDOC suppresses the activity of 
the PCtx circuit, and kinase activation, in general, suppressed the effect of THDOC.  
 Effect of THDOC on PCtx circuit 
We found that 100 nM THDOC application suppressed the activity of all 3 layers involved 
in the PCtx feed-forward disinhibitory circuit (PCtx layer II, III, and DEn).This is in line 
with our previous study that found that THDOC enhanced both miniature IPSCs (mIPSCs) 
and tonic inhibition in layer II pyramidal cells (Kia et al., 2011). We speculate that this is 
because the pyramidal cells are dampened, especially by enhanced tonic inhibition. This 
reduced activation from layer II results in reduced activation of DEn and thus less 
disinhibition. As a result, the overall activity of the circuit is reduced. A previous study has 
also shown that mIPSCs of layer III interneurons are enhanced by THDOC (Gavrilovici et 
al., 2006). This may have further contributed to reducing the activity of the circuit.  
 Effect of PMA – PKC activation 
We found that PKC activation by PMA reduced the activity of the PCtx circuit in response 
to LOT stimulation. THDOC failed to suppress the circuit in the presence of PMA, and 
even seem to increase circuit activity in layer III and DEn, close to control response. The 
reduction of PCtx activity by PMA was expected, as previous investigation from our 
laboratory showed that PKC activation, via activation of Gαq/11 using corticotropin 
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releasing factor (CRF), suppressed circuit activity (Narla et al., 2015, 2016). This was due 
to increased accommodation of the pyramidal cells as they generated fewer action 
potentials following stimulation when treated with CRF. While little is known on how the 
interneurons in layer III and DEn are modulated, previous studies have shown that layer 
III interneurons have highly variable response to CRF (Gavrilovici et al., 2006; Narla et 
al., 2015). As CRF in the region typically signal via Gαq/11 (which activates PKC pathway), 
it is likely that the responses of interneurons to PKC are also variable. Due to their 
variability, the reduction in overall circuit activation by PKC is likely a result of dampening 
of layer II.  
THDOC, when PKC was activated, did not alter the activation of layer II, in line with our 
previous findings in single-cell recordings of pyramidal cells (Kia et al., 2011). Reduced 
(or lack of) THDOC effect on the circuit is likely due to the effect of PKC, as PKC 
activation greatly reduces THDOC efficacy on mIPSCs and blocks enhancement of tonic 
inhibition.   
 Effect of forskolin – PKA activation 
Activation of PKA by forskolin did not change the activity of the PCtx circuit in response 
to LOT stimulation. However, this treatment blocked the inhibitory effects of THDOC on 
this circuit. In Chapter 2, we showed that PKA activation greatly suppressed THDOC 
efficacy on potentiating tonic inhibition in cortical pyramidal cells. Thus, we speculate that 
a similar mechanism takes place in PCtx neurons, and THDOC no longer potentiates 
GABAergic inhibition and thus ineffective in reducing the circuit activation by LOT 
stimulation. Specifically, phosphorylation of layer II pyramidal cells is likely responsible 
for suppression of THDOC effect. As PKA phosphorylation is known to dampen the effect 
of THDOC on tonic inhibition, suppressing potentiation of tonic inhibition in layer II may 
reduce or abolish the effect of THDOC in the circuit. PKA activation in the interneuron 
layers (layer III and DEn) may only play a small role as the cell populations are much more 
diverse, and their responses to kinases vary from cell to cell (Gavrilovici et al., 2006, 2010, 
2012). However, the exact mechanisms by which PKA activation abolishes the effects of 
THDOC in PCtx warrants further studies.  
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 Effect of 7,8-DHF – TrkB activation 
TrkB agonist 7,8-DHF alone did not change the activity of the PCtx circuit. However, 
similar to the case of forskolin, it blocked the inhibitory effect of THDOC on the circuit. 
As TrkB has been shown to activate PKC signaling, we initially predicted that TrkB alone 
may have an inhibitory effects similar to PKC (Jovanovic et al., 2004; Nakamura et al., 
2015b). Thus, the lack of effects by TrkB alone hint that in PCtx circuit neurons, TrkB may 
not substantially activate signaling pathways converging to PKC activation. 
Activation of TrkB also suppressed THDOC-mediated suppression of the circuit activity 
in response to LOT stimulation. We interpret this is because TrkB suppresses THDOC-
mediated potentiation of tonic inhibition. Previous report on cortical pyramidal cells 
showed that TrkB greatly reduced potentiation of tonic inhibition (Chapter 2). If the effects 
on the layer II pyramidal cells are similar, this may greatly reduce the efficacy of THDOC 
on suppressing the circuit activity. Another possibility is brain-derived neurotrophic factor 
(BDNF)-mediated suppression of potassium-chloride cotransporter 2 (KCC2). BDNF, via 
its receptor TrkB, can down-regulate KCC2 (Rivera et al., 2002). Reduction in KCC2 
results in reduced chloride gradient and make GABAergic inhibition less effective. TrkB 
activation by BDNF has been linked to induction/establishment of epileptic activity (Rivera 
et al., 2002; Wake et al., 2007). Reduced efficacy of GABAergic inhibition may act to 
dampen the potentiating effect of THDOC. However, it is unclear whether the expression 
of KCC2 can be altered so rapidly, as our experiments looked at acute effects of kinases 
and THDOC (10-30 min).  
 Conclusion 
In this study, we investigated the effects of three kinase activators (PKC, PKA, and 
TrkB) and the inhibitory neurosteroid THDOC in the PCtx circuit. We also examined 
whether kinase activation can alter the effect of THDOC on this circuit. We found that 
THDOC reduced the activity of the PCtx disinhibitory circuit in all 3 layers involved. All 
kinase activators tested greatly reduced the inhibitory effect of THDOC. Kinases are 
known to suppress the enhancement of tonic inhibition by THDOC in pyramidal cells. 
This is likely main reason why THDOC showed reduced efficacy when treated with 
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kinase activators. As changes to kinase activities have been linked to epilepsy (Rivera et 
al., 2002; Kia et al., 2011), it may be of great interest to investigate how effects of these 
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Chapter 5  
5 Kinase activation restores neurosteroid-induced 
suppression of the piriform cortex in epileptic rats 
 Introduction 
Epilepsy is one of the most common neurological disorder affecting approximately 50 
million people worldwide (World Health Organization, 2019). Studies suggest that over 
30% of the patients are drug resistant, continue to suffer from seizures despite extensive 
pharmacological interventions, many of which are often associated with severe side-effects 
(Ngugi et al., 2010; Gaitatzis & Sander, 2013). Temporal lobe epilepsy (TLE) is the most 
common type of epilepsy with focal seizures, with high  rate (55-80%, depending on the 
study) of drug resistance (Semah et al., 1998; Jallon et al., 2001; Morimoto et al., 2004; 
Kuzmanovski et al., 2016; Sheng et al., 2018). 
Neurosteroids, steroid metabolites that modulate neuronal excitability, have been shown to 
have anti-seizure effects and are being tested for use as anti-seizure medication (Kaminski 
et al., 2004; Biagini et al., 2010; Reddy & Rogawski, 2010). Such inhibitory neurosteroids 
potentiate GABAergic inhibition by prolonging the time course (i.e. decay) of inhibitory 
post synaptic currents (IPSCs) and by enhancing tonic inhibition mediated by extrasynaptic 
GABAA receptors (Majewska et al., 1986; Wohlfarth et al., 2002; Schwabe et al., 2005; 
Kia et al., 2011).  
We have previously shown that the neurosteroid tetrahydrodeoxycorticosterone (THDOC) 
suppresses the activity of rat piriform cortex circuit (PCtx), and that this inhibitory action 
of THDOC is suppressed by activation of protein kinases in primary cultures of cortical 
neurons (Chapter 2). PCtx, a part of the olfactory cortex, is one of the most seizure-
susceptible regions of the brain (Löscher and Ebert, 1996; Vaughan and Jackson, 2014). 
This is perhaps due to its dense connections to other regions of the brain involved in 
epilepsy/epileptogenesis such as the amygdala, hippocampus and the entorhinal cortex 
(Krettek and Price, 1978a, 1978b; Wakefield, 1980). PCtx contains a feed-forward 
disinhibitory circuit that is thought to be involved in epilepsy (Birjandian et al., 2013). This 
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circuit involves layer II and III of the PCtx and the adjacent dorsal endopiriform nucleus 
(DEn). 
Using kindling, a phenomenon where repeated stimulation of limbic region results in 
seizures (a model of TLE), our laboratory previously showed that the inhibitory effects of 
THDOC (i.e. potentiation of IPSCs) decreases in layer II pyramidal cells, and this change 
was due to protein kinase C activation (Kia et al., 2011). However, the effect of kinases 
and neurosteroids in other layers of the PCtx circuit remains unknown. Furthermore, due 
to the complexity of the circuit, which involves disinhibition, it is unclear how THDOC 
will alter the PCtx circuit excitability following kindling and expected activation of 
intracellular kinase activities. To address this question, in the present study, we investigated 
the effect of the neurosteroid THDOC on PCtx circuit excitability in slices prepared from 
kindled rats utilizing voltage sensitive dye imaging (VSDI). This technique allows for 
visualization of neuronal activity in a large area of the brain, suitable for investigating 
circuit activity (Birjandian et al., 2013). We also asked how the effects of THDOC will be 
modulated by PKC in brain slices from kindled rats. 
 Materials and Methods 
All experiments were performed in accordance with the guidelines of Canadian Council on 
Animal Care and approved by the University of Western Ontario Animal Care Committee 
(AUP 2010-017, 2018-083). No animal has been excluded. No randomization was 
performed to allocate subjects in the study. No blinding was performed during the 
experiments.  
 Surgery and kindling 
Male Sprague Dawley rats (Charles River Laboratories, Quebec, Canada) weighing 200 to 
300 g were used in the experiments. Animals were housed individually with free access to food 
and water under 12-hour light and dark cycle. Animals were anaesthetized with ketamine-
medetomidine HCl combination and put under 2% isoflurane to maintain anesthesia throughout 
surgery. They were implanted with two bipolar electrodes bilaterally in basolateral amygdala 
(Gavrilovici et al., 2006). Implanted electrodes were secured to the skull with jeweler’s screws 
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and fixed to skull by dental acrylic cement. Kindling took place 1 week after the surgery to 
allow for rats to recover from the surgery.  
Kindling is a phenomenon where repeated stimulation of the limbic region (e.g. amygdala, 
hippocampus) results in seizures and epilepsy, and it is widely used to study TLE (Racine, 
1972a, 1972b; Morimoto et al., 2004). Rats were stimulated daily until three stage 5 seizures 
were elicited. Detailed kindling procedure is described elsewhere (Gavrilovici et al., 2006).  
 Brain slice preparation 
Animals were anaesthetized with ketamine-medetomidine HCl combination and perfused 
with ice-cold artificial cerebrospinal fluid (ACSF) with choline ions replacing sodium ions. 
ACSF composition was as follows: 100 mM choline Cl, 2.5 mM KCl, 1.2 mM NaH2PO4, 
25 mM NaHCO3, 0.5 mM CaCl2, 7 mM MgCl2, 2.4 mM Na pyruvate, 1.3 mM ascorbate, 
and 20 mM D-glucose. After perfusion, the brain was rapidly removed, and the brain was 
sliced using Vibratome into 400-μm slices. The slices were incubated in 37˚C ACSF bath 
for 35 min and then in room temperature (22˚C) bath for 45 min. The ACSF during 
perfusion, slicing, and incubation was supplied with carbogen (95% O2 and 5% CO2 
mixture). 
 Voltage sensitive dye staining and imaging 
After incubation, slices were incubated in the voltage sensitive dye Di-4-ANEPPS. Dye 
incubation solution consisted of 60 μM of dye stock, 500 μM, and 500 μM of bicarbonate 
ACSF.  Final dye concentration in the solution was 0.1 mg/mL. The bicarbonate ACSF 
was composed of 110 mM NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 25 mM NaHCO3, 2.0 
mM CaCl2, 2.0 mM MgCl2, and 20 mM D-glucose. The pH was between 7.3 and 7.4 and 
the osmolarity was 297 to 305 mOsm. After 30 min incubation in the dye solution, slices 
were washed with the bicarbonate ACSF to remove excess dye. Then, the slices were 
transferred to a recording chamber supplied with carbogen-bubbled 32°C bicarbonate 
ACSF. A platinum-iridium electrode with a tip diameter of 200-300 μm (MicroProbes, 
Gaithersburg, MD, USA)  was used to stimulate the LOT of the PCtx (Narla et al., 2016).  
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MiCAM ULTIMA complementary metal-oxide-semiconductor (CMOS) camera system 
(Brainvision Inc., Tokyo, Japan) was used to record the optical signals. CMOS camera was 
mounted on fixed-stage upright microscope (BX51WI, Olympus Corporation, Tokyo, 
Japan). Slices were illuminated using 100-W halogen lamp source passed through 
excitation filter (λ = 530 ± 10 nm). A long-pass emission filter (λ > 590 nm) collected the 
fluorescent signals. Objective used in the experiments was 4× long working distance 
objective (NA = 0.28, Olympus Corporation). Obtained data was analyzed using 
BV_Analyzer (Brainvision Inc.) Detailed explanation of the analysis is described 
elsewhere (Birjandian et al., 2013). Change in fluorescence signal relative to the 
background (ΔF/F) was calculated for each frame of the recordings. As there is variability 
in response from slice to slice due to loading of the dye, all recordings are normalized by 
dividing all signals by response to the control 20 Hz stimuli. The stimulus frequencies 
tested were 10, 20, 40, 60, and 80 Hz.   
 Reagents 
Di-4-ANEPPS (D8064, Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 100% 
ethanol (EtOH) at 22 mg/mL. THDOC (P2016, Sigma-Aldrich) was dissolved in 100% 
EtOH at 10 mM, and this stock was diluted to final concentration of 100 nM in the external 
solution (final EtOH 0.001%). PKC was activated using 100 nM phorbol 12-myristate 13-
acetate (PMA; 1201, Tocris Bioscience, Bristol, UK). PMA and THDOC were applied in 
bath for minimum of 10 min. 
 Statistical analysis 
All statistical analyses were done using Prism 8.4.2 (GraphPad Software Inc., San Diego, 
CA, USA). Comparison of all data was done using repeated-measures two-way analysis of 
variance (ANOVA), followed by Fisher’s least significance difference test. The 





 THDOC does not alter PCtx circuit activity after kindling 
We have previously shown that stimulation of the lateral olfactory tract (LOT) (20-80 Hz 
stimulus) activates the PCtx feed-forward disinhibitory loop (Birjandian et al., 2013). 
Stimulation of LOT activates the apical dendrites of layer II pyramidal cells of the PCtx. 
The layer II cells then activate DEn interneurons. DEn interneurons inhibit the layer III 
interneurons that innervate layer II pyramidal cells. This disinhibition suppresses 
attenuation of the stimulus signal, resulting in prolonged circuit activity. In Chapter 4, we 
showed that THDOC suppressed the activity of the whole circuit in naïve (non-kindled) 
PCtx (Figure 4.2).  
In contrast to this potent inhibitory effect, in slices prepared from kindled rats, the 
application of 100 nM THDOC did not alter the activity of all 3 layers, layer II, III and 
DEn in response to LOT stimulation (Figure 5.1). THDOC did not alter the activation of 
layer II (F1,40 = 0.00, P > 0.05, n = 9). For DEn, while the ANOVA was significant (F1,40 
= 6.06, P < 0.05), the post-hoc analysis was not (P > 0.05 for all frequencies tested), 
suggesting THDOC does not alter DEn activation. The deactivation of layer III did not 
change with THDOC administration (F1,40 = 2.66, P > 0.05).   These data indicate that the 






Figure 5.1 THDOC did not alter the activity of the PCtx circuit evoked by LOT 
stimulation in kindled rats.  
(A,B) Voltage sensitize dye imaging shows activation of layer II PCtx and dorsal 
endopiriform nucleus (DEn) and deactivation of layer III PCtx. The activities of (C) layer 
II, (D) layer III, and (E) DEn did not change with THDOC administration at all stimulus 





 PKC activation restores THDOC effect 
In Chapter 4, prior PKC activation was shown to abolish the inhibitory effects of THDOC 
in PCtx cortex. Thus, our working hypothesis is that kindling activates PKC, which in turn 
blocks the effects of THDOC on PCtx neurons. If this is the case, an additional 
pharmacological activation of PKC with 100 nM PMA (this alone had an inhibitory effect, 
see Figure 4.3) should occlude with kindling. In line with the prediction, PMA did not alter 
the activity of the PCtx circuit (Figure 5.2). However, subsequent 100 nM THDOC 
application unexpectedly decreased PCtx circuit activity. Specifically, in the presence of 
PKC activator PMA, THDOC significantly reduced the activation of layer II at 60 and 80 
Hz stimulation (P < 0.05 and P < 0.01, respectively; n = 4). For DEn, THDOC 
administration after PMA, slightly reduced the activation of DEn neurons, although the 
effect was not statistically significant (F2,30 = 3.18, P = 0.056). In layer III, THDOC 
significantly reduced the deactivation at 60 and 80 Hz (P < 0.001 at both frequencies). At 
60 Hz, THDOC treatment was significantly smaller than PMA treatment alone (P < 0.05). 
At 80 Hz, PMA treatment alone resulted in decreased deactivation, but this is likely due to 
small sample size (n = 4). These data indicate PKC activation by PMA makes THDOC 






Figure 5.2 Activation of PKC by PMA restored suppressive effect of THDOC on the 
PCtx circuit  
(A-C) Representative VSDI of the PCtx at 80 Hz stimulation. (D) Layer II activation was 
not altered by PMA, but subsequent THDOC administration decreased the activation at 60 
and 80 Hz stimulation. (E) In layer III, THDOC suppressed the deactivation of the layer at 
60 and 80 Hz sitmuation. (F) For DEn, THDOC appears to decrease the activation of the 
layer, but it was not statistically significant (P = 0.056). (*P < 0.05 for control vs. PMA + 
THDOC; **P < 0.01 for control vs. PMA + THDOC; ***P < 0.001 for control vs. PMA + 






We have previously reported on the effects of the neurosteroid THDOC on PCtx circuit 
and how kinase activation modulated THDOC-induced suppression of the circuit activity 
(Chapter 4). PCtx is one of the most seizure-susceptible regions of the brain, and previous 
studies suggest that the PCtx circuit may play a role in epilepsy (Birjandian et al., 2013; 
Narla et al., 2016, 2019). Yet, little is known how PCtx is modulated or how its activity 
changes after kindling (epilepsy). As such, in this study, we investigated the activity of the 
neurosteroid THDOC and how different kinases modulate its activity in the PCtx circuit. 
We found that THDOC had no effect in the PCtx of kindled rats. While the activation of 
PKC activity by PMA did not have any effect on the circuit activity, subsequent THDOC 
administration suppressed the circuit activation.  
 Effect of THDOC on PCtx after kindling 
We found that 100 nM THDOC did not alter the activity of the PCtx in response to LOT 
stimulation after kindling. This contrasts with what occurs in naïve PCtx, where THDOC 
reduced the activity of the circuit in response to LOT stimulation (Chapter 4). Using whole 
cell patch-clamp recording from layer II pyramidal cells, previous studies found that 
THDOC-mediated enhancement of GABAergic currents is reduced after kindling 
(Gavrilovici et al., 2006; Kia et al., 2011). Specifically, kindling greatly reduced the 
enhancement of miniature IPSCs (mIPSCs) and abolished enhancement of tonic inhibition 
by THDOC. The suppressive effect of THDOC on the circuit in naïve brain is likely due 
to enhanced tonic inhibition, combined with enhanced IPSCs, as these would dampen the 
response of the pyramidal cells in response to LOT stimulation and strengthen inhibition 
of the pyramidal cells. As kindling suppresses enhancement of GABAergic inhibition of 
the pyramidal cells by THDOC, there would be great reduction in efficacy of THDOC in 
modulating the PCtx circuit.    
 Effect of PMA – PKC activation 
After kindling, PKC activation by 100 nM PMA did not change the activity of the PCtx. 
Previous reports on naïve PCtx found that PMA reduced the activity of the circuit in all 
three layers (Chapter 4; Narla et al. 2015). This may be because GABAA receptors are 
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already phosphorylated by PKC after kindling, as reported by Kia et al. (2011). The study 
has shown that kindling enhances phosphorylation state of GABAA receptors mediated by 
PKC (Kia et al., 2011). Thus, further increase in PKC activity by PMA may have little to 
no effect on already phosphorylated GABAA receptors in layer II pyramidal cells.  
Surprisingly, THDOC application following PMA treatment resulted in reduction of PCtx 
activity; in other words, PMA partially restored the inhibitory effect of THDOC. As stated 
previously, kindling abolishes inhibitory actions of THDOC via PKC activity in layer II 
pyramidal cells (Kia et al., 2011), so it seems unlikely that these cells are responsible for 
the inhibitory effect of THDOC. A previous report has shown that the effect of THDOC 
on mIPSCs of interneurons in the PCtx are unaffected by kindling (Gavrilovici et al., 2006). 
This suggests that kindling may activate PKC (and thus blocks the effects of THDOC) in 
cell-type specific manner and may not affect layer III and DEn through PKC. As such, they 
can be modulated by PKC activator.  
We speculate that in the kindled brain, THDOC application following PKC activation 
results in decreased disinhibition of the circuit, leading to reduced circuit activity. 
Decreased efficacy of THDOC in layer III interneurons via PKC phosphorylation of 
GABAA receptors will lead to increased inhibition of layer II, and thus suppressed circuit 
activity. Another possibility is that PKC activation enhances THDOC activity in DEn. This 
will lead to decreased inhibition of Layer III cells, leading to decreased disinhibition. While 
our laboratory’s studies in cortical pyramidal cells and layer II pyramidal cells have shown 
that PKC suppresses the effect of THDOC, other studies looking at different cell 
populations have shown that PKC activation can enhance neurosteroid activities 
(Leidenheimer and Chapell, 1997; Harney et al., 2003; Lambert et al., 2003). The 
differences in the effect of PKC may be due to differences in GABAA receptor subunit 
expression. Indeed, past studies have shown that GABAA receptor subunit protein and 
mRNA expression patterns of PCtx and endopiriform nucleus are different (Fritschy & 
Mohler, 1995; Hörtnagl et al., 2013). However, as very little is known on how the 
interneurons of PCtx are modulated at cellular level, it is unclear which (or both) is true 




In the present study, we investigated the effects of the neurosteroid THDOC and PKC and 
PKA in PCtx circuit after kindling, a model of TLE. We have also examined how kinase 
activation alters the effect of THDOC. We observed that THDOC did not alter the activity 
of the PCtx circuit following LOT stimulation, unlike in naïve rats where it suppresses the 
activity. PKC activation, which in healthy PCtx suppresses activity, also did not change 
the circuit activity. However, PKC activation restored the normal effect of THDOC as 
subsequent THDOC administration resulted in decreased activity in all 3 layers of the 
circuit. Our findings show that kindling alters the efficacy of neurosteroids, and that 
regulation of protein kinase activity (PKC) may be able to restore normal activity of 
neurosteroids. Phosphorylation may be an important mechanism in drug-resistance seen in 
epilepsy, as other anti-epileptic drugs (e.g., benzodiazepines and barbiturates) can also be 
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Chapter 6  
6 General Discussion 
GABAA receptors are the main driver of inhibition in the CNS. These GABA-gated 
chloride ion channels mediate both fast synaptic inhibition, as well as sustained tonic 
inhibition at extrasynaptic membrane. Regulation of GABAA receptor activities is vital in 
normal physiological functioning of the brain, and as such, changes to GABAergic 
inhibition (by both endogenous and exogenous molecules) can result in various 
physiological and pathological changes that affect brain development (Brussaard et al., 
1997; Koksma et al., 2003), mood and anxiety (Nutt & Malizia, 2001; Kalueff & Nutt, 
2007), and seizure activities (Treiman, 2001; Fritschy, 2008; Tuveri et al., 2008; Kia et al., 
2011).   
Various endogenous molecules can modulate GABAergic function. In particular, 
neurosteroids, metabolites of steroid hormones, are potent modulators of GABAA receptors 
(Lambert et al., 2003). The effects of neurosteroids vary across different brain regions, and 
different cell types/preparations (Jussofie, 1993; Cooper et al., 1999). One possible reason 
for this variability is the phosphorylation state of GABAA receptor, which differs by brain 
area, cell type and/or brain state. Thus, this thesis examined the effects of activation of 
three major kinases, PKC, PKA, and TrkB, on modulating neurosteroids’ ability to alter 
GABAergic transmission. We first examined this at the cellular level, examining the 
kinetics of phasic IPSCs and tonic currents in cells morphologically identified to be 
pyramidal cells in primary cortical neuronal culture (Chapter 2 & 3). Next, we examined 
the effects of neurosteroid and kinase modulation at circuit level, in acute slices containing 
the PCtx circuit (Chapter 4). Lastly, we investigated how the actions of neurosteroid and 
kinase modulation changes in the PCtx of a rat kindling model of epilepsy (Chapter 5). 
PCtx is one of the most seizure-susceptible regions of the brain, and previous studies in 
this region have reported changes to phosphorylation of GABAA receptors may be 
implicated in pathological changes in epilepsy (Gavrilovici et al., 2006a; Kia et al., 2011; 
Narla et al., 2016a). 
129 
 
We found that at cellular level, kinases differentially modulate the effects of inhibitory 
neurosteroid THDOC on phasic and tonic inhibition. Overall, kinases (PKC, PKA, and 
TrkB) did not alter the ability of THDOC in enhancing IPSCs by prolonging the decay. 
However, all three kinases greatly suppressed THDOC-mediated potentiation of tonic 
inhibition (Chapter 2). The effect of excitatory neurosteroid PregS on suppressing IPSC 
was not modulated by kinase activation. In addition, PregS, with or without kinase 
activation, did not modulate tonic inhibition (Chapter 3).    
In the PCtx circuit, THDOC suppressed the activity of the circuit in response to LOT 
stimulation. By contrast, kinase activations (PKC, PKA or TrkB) prior to THDOC 
application abolished the effects of THDOC, indicating modulatory roles of kinases on 
THDOC actions in the PCtx circuit. However, PKC activation alone, but not PKA or TrkB, 
reduced the activity of the circuit, pointing to multiple mechanisms for the kinase 
modulation of THDOC actions (Chapter 4).  
In kindled brain, THDOC failed to suppress PCtx circuit activity. Similarly, we also 
observed loss of effect of PMA, as it did not alter the circuit activity. However, subsequent 
THDOC application resulted in decreased activity, seemingly restoring the efficacy of 
THDOC (Chapter 5). 
 Modulation of THDOC vs. PregS by protein kinases 
In chapters 2 and 3, we studied the effects of kinase activators on neurosteroids’ ability to 
modulate GABAergic inhibition. We found that the effects of inhibitory neurosteroid 
THDOC on GABAA receptors are modulated by protein kinases, but the effects of 
excitatory neurosteroid PregS are not. For inhibitory neurosteroids like THDOC, it is well 
known that protein kinases can modulate its efficacy on GABAergic inhibition, though the 
exact effect of kinase activation differ depending on brain region or cell preparations 
(Leidenheimer and Chapell, 1997; Harney et al., 2003; Kia et al., 2011; Adams et al., 2015). 
In oocytes expressing α1β2γ2L, PKC activation enhanced THDOC-mediated potentiation of 
GABAA receptor currents (Leidenheimer & Chapell, 1997). Similarly, in HEK293 cells 
expressing α1β3γ2L receptors, PKC activation enhanced the effect of THDOC (Adams et 
al., 2015). In contrast, PKC activation in layer II pyramidal cells of PCtx decreased 
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THDOC efficacy on GABAergic currents (Kia et al., 2011), and similar effects were seen 
in neurons of supraoptic nucleus with allopregnanolone (Koksma et al., 2003). In our study 
using cultured cortical neurons (Chapter 2), we saw that protein kinase activation had little 
to no effect on mIPSCs (but had great suppressive effect on potentiation of tonic currents). 
These data show that protein kinase activation, and presumably phosphorylation of 
GABAA receptors, can act synergistically with inhibitory neurosteroids to enhance 
inhibition of specific brain regions/cell populations or can suppress neurosteroid effect to 
dampen inhibition. The interaction of protein kinase and inhibitory neurosteroid is perhaps 
essential in maintaining normal physiological functioning of the brain, as changes to kinase 
activity or phosphorylation state of GABAA receptor is associated with kindling and 
perhaps epilepsy (Chapter 4, 5; Kia et al., 2011; Narla et al., 2015, 2016). 
In contrast to THDOC and other inhibitory neurosteroids, excitatory neurosteroid PregS 
was not modulated by protein kinase activities (Chapter 3; Leidenheimer and Chapell, 
1997). This is perhaps not so surprising, given that excitatory neurosteroids are thought to 
bind to a different site from inhibitory neurosteroids (Majewska et al., 1990; Park-Chung 
et al., 1999; Hosie et al., 2007; Laverty et al., 2017a). A recent crystal structure study of 
GABAA receptor chimera proposed that THDOC binding site is located across subunit-
subunit interface, and THDOC binds to M1 domain of one subunit and M3 of adjacent 
subunit (Laverty et al., 2017a). The same study showed that PregS binds to a distinct intra-
subunit site at M3 and M4 domains. As THDOC and PregS bind to different sites, they are 
likely differentially modulated by kinase activities.  
Past studies have shown that PregS is a positive allosteric modulator of N-methyl-D-
aspartate (NMDA) receptor (Wu et al., 1991; Bowlby, 1993; Ceccon et al., 2001). The 
effect of PregS on NMDA receptors can be modulated by protein kinase activities (Dong 
et al., 2005; Petrovic et al., 2009). Dong et al. (2005) showed that blocking PKA and PKC 
activities reduced the PregS-mediated increase in miniature excitatory postsynaptic current 
frequency in pyramidal cells of layer V-VI of prelimbic cortex. Another group showed that 
PKA inhibitor decreased PregS-induced potentiation of NMDA receptor currents, and this 
decrease was recovered by adding PKA activator (Petrovic et al., 2009). Thus, we speculate 
that excitatory neurosteroids may act broadly to dampen GABAergic transmission but have 
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more cell-type or brain region specific effects on excitatory neurotransmission, similar to 
effects of inhibitory neurosteroids on inhibition.  
Aside from its typical allosteric action, recent studies have shown that THDOC can also 
modulate GABAA receptors via metabotropic action. (Modgil et al., 2017; Parakala et al., 
2019). Specifically, THDOC activates membrane progesterone receptors, a G protein-
coupled receptor, which results in PKA- and PKC-mediated phosphorylation of S408/9 of 
β3 subunit (Parakala et al., 2019). The study demonstrated that phosphorylation of these 
residues resulted in enhanced tonic inhibition, and this effect was slow acting, becoming 
effective after 15 min exposure to THDOC followed by 30-50 min wash. In our 
investigation, we saw the potentiating effect of THDOC on tonic inhibition within minutes 
of its application and the peak effect was seen by ~5 min. Thus, as THDOC effects in our 
studies were rapid, we conclude that the THDOC actions seen in our studies are the result 
of allosteric actions of THDOC.   
 Kinase modulation of THDOC activity at cellular level vs.  
    PCtx circuit 
In chapter 4, we studied kinase modulation of THDOC activity at circuit level in the PCtx 
and found that, similar to our cellular data, kinase activation reduced the suppression of 
PCtx circuit activity by THDOC.   
We speculate that the abolishment of THDOC effect in PCtx circuit is mainly due to 
reduced tonic inhibition as a result of kinase activation. Since the kinases suppress the 
effect of THDOC, the layer II pyramidal cells are not dampened by enhanced tonic 
inhibition seen with THDOC without kinase treatment. Thus, THDOC loses its inhibitory 
effect in the circuit. In other words, as layer II is the main driver (major excitatory input) 
of the whole circuit, dampening of layer II resulted in decreased activity of the whole 
circuit. We speculate that layer III and DEn responses to THDOC after kinase treatment 
either does not change or the changes were not large enough to affect the activity of the 
whole circuit. This is in line with a previous study that looked at mIPSC and tonic inhibition 
of layer II pyramidal cells (Kia et al., 2011). The study found that PKC activation abolishes 




While kinase modulation of THDOC activity at cellular level (in cortical pyramidal cells) 
and at circuit level (in PCtx) is mostly consistent, there is a small discrepancy in action of 
PMA (PKC activator) on mIPSCs. In putative pyramidal cells, we saw that PKC activation 
does not alter the effect of THDOC on mIPSC kinetics. However, in layer II pyramidal 
cells of PCtx, a past study has shown that PKC activation by PMA greatly reduced the 
effect of THDOC (Kia et al., 2011). This difference is likely due to differences in GABAA 
receptor subunit expression (Wisden et al., 1992; Fritschy & Mohler, 1995). 
Immunofluorescence staining showed that while PCtx layer II shows low α1 
immunoreactivity, it is relatively high in the neocortex (Fritschy & Mohler, 1995). Layer 
II PCtx also shows intense immunofluorescence staining and mRNA expression of α2, 
compared to weak to moderate staining/expression in neocortex (Wisden et al., 1992; 
Fritschy & Mohler, 1995).  
 THDOC and kinase activity in naïve brain vs. kindled  
    brain 
In chapter 4, we studied the effects of THDOC, kinase activation, and kinase modulation 
of THDOC effect in the PCtx of naïve brain, and in chapter 5, we followed up by looking 
at PCtx of kindled (epileptic) brain. We found that kindling changes the effects of PKC, 
THDOC, and PKC-mediated modulation of THDOC.  
We found that while THDOC suppressed the activity of PCtx in naïve brain, its effect was 
lost in the kindled brain. This is in line with previous studies that looked at PCtx layer II 
pyramidal cells after kindling (Gavrilovici et al., 2006; Kia et al., 2011). These studies 
found that THDOC does not potentiate GABAA receptor-mediated mIPSCs in layer II 
pyramidal cells after kindling. The two most likely candidates responsible for the 
abolishment of THDOC after kindling are changes to GABAA receptor subunit 
composition and changes to modulation of the receptors via protein kinase-mediated 
phosphorylation. Seizures/epilepsy are associated with changes to GABAA receptor 
subunit expression (particularly in the hippocampus) in human patients and in various 
animal models (Nusser et al., 1998; Brooks-Kayal et al., 1998; Fritschy et al., 1999; Loup 
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et al., 2000; Peng et al., 2004; Nishimura et al., 2005; Drexel et al., 2013). In rat 
pilocarpine-induced status epilepticus model, dentate gyrus cells showed decreased relative 
mRNA expression of α1 and β2 and increased expression of α4, β3, and δ subunits (Brooks-
Kayal et al., 1998). Hippocampal kindling resulted in decreased mRNA level of δ subunit 
in dentate gyrus and increased level of all three β subunits, γ2, and α4 subunits in rats 
(Nishimura et al., 2005). In human temporal lobe epilepsy (TLE) patients, decreased 
expression of α2 subunit was observed throughout hippocampus proper, with layer specific 
changes to other subunits including α1 β2/3 and γ2 (Loup et al., 2000). However, this is not 
likely the case in the PCtx, as previous report found no changes in subunit expression of 
the pyramidal cells after kindling in rats (Kia et al., 2011). Thus, changes to 
phosphorylation state of the receptor seem the most likely reason for abolishment of 
THDOC effect. Indeed, previous report showed that PKC activation is likely responsible 
for suppressing the effect of THDOC in the PCtx layer II (Kia et al., 2011). This is also in 
line with our patch clamp results (Chapter 2), as we demonstrated that activation of protein 
kinases (and thus phosphorylation of GABAA receptors) suppress THDOC-mediated 
potentiation of tonic current.  
Regarding the effect of PKC activation, we found that in naïve brain, PKC suppresses the 
activity of the PCtx circuit. However, in kindled brain, PKC activation had little to no effect 
on the activity of the circuit. This is perhaps because after kindling, the GABAA receptors 
in layer II PCtx neurons are already phosphorylated by PKC. Previous report study showed 
that there is enhancement of PKC-mediated phosphorylation in layer II pyramidal cells 
(Kia et al., 2011). Since the neurons are already phosphorylated, further activation of PKC 
may not have any effect.  
In the naïve brain, activation of PKC abolished the effect of THDOC. However, in kindled 
brain, THDOC application following PKC activation resulted in suppression of the circuit. 
Thus, on appearance PKC activation restored the inhibitory effect of THDOC in kindled 
brain. While the reasons for this paradoxical effect require further investigation, we 
speculate that kindling phosphorylates GABAA receptors in specific cell-types of PCtx 
circuit whereas pharmacological PKC activation affects all cell types. Our previous study 
showed that kindling phosphorylates GABAA receptors  and abolished THDOC effects in 
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the layer II pyramidal cells (Kia et al., 2011). On the other hand,  the interneurons of layer 
III are seemingly unaffected by kindling, as they still responded to THDOC with the 
potentiation of mIPSCs (Gavrilovici et al., 2006). Thus, the interneurons of layer III, and 
perhaps DEn, may remain unphosphorylated in kindled brain and can be phosphorylated 
by PKC activation. Phosphorylation of the interneuronal layers cause changes to the 
activity of the circuit so that THDOC application leads to decreased disinhibition (or 
increased inhibition of layer II) in the circuit, suppressing the circuit activity.  
This may happen in two ways: decreased efficacy of THDOC in layer III and/or enhanced 
efficacy of THDOC in DEn. Decreased efficacy of THDOC in layer III will reduce the 
efficacy of inhibitory input from DEn. Furthermore, there will be reduced enhancement of 
tonic inhibition of layer III interneurons due to PKC activation. As such, there will be 
increased inhibition of layer II pyramidal cells, leading to decreased activity of the circuit. 
On the other hand, enhanced efficacy of THDOC in DEn will potentiate tonic inhibition of 
the DEn interneurons, reducing the strength of inhibitory transmission to layer III. This 
will lead to increased activity of layer III and suppress activation of layer II, reducing the 
circuit activity. PKC phosphorylation enhancing the effect of THDOC is opposite of what 
our study has demonstrated, but previous studies in different populations of neurons have 
shown that PKC activation can enhance neurosteroid activities (Leidenheimer and Chapell, 
1997; Harney et al., 2003; Lambert et al., 2003; Adams et al., 2015). It is however unclear 
which of the two mechanisms (or both) is true, due to the diversity of interneurons in the 
PCtx and DEn (Suzuki & Bekkers, 2007; Gavrilovici et al., 2010), and limited information 
on how their activities are modulated. Further research in characterizing the interneurons 
involved in the PCtx circuit and their responses to neurosteroids and kinases may provide 
more insight.  
 Chloride homeostasis 
Maintaining low intracellular chloride ion concentration ([Cl−]i) is essential for the 
inhibitory function of GABAA receptors. Inhibition by GABAA receptor is driven by 
relatively low [Cl−]i, as the concentration gradient drives the influx of Cl−. This gradient is 
thought to be maintained primarily by ion transporters like K+-Cl− cotransporter 2 (KCC2) 
(Vogt, 2015). Indeed, downregulation of KCC2 (by pharmacological/posttranslational 
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modifications or mutations) has been associated with seizures/epilepsies (Woo et al., 2002; 
Tornberg et al., 2005; Huberfeld et al., 2007). Mice homozygous for non-functional KCC2 
exhibited spontaneous generalized seizures and died within 3 weeks after birth (Woo et al., 
2002; Tornberg et al., 2005). Heterozygous mice showed increased seizure susceptibility 
(Tornberg et al., 2005). In tissues of mesial TLE patients, there was decrease in KCC2 
expression in subicular pyramidal cells, and in cells with undetectable immunostaining for 
KCC2 showed depolarizing GABAergic synaptic potential (Huberfeld et al., 2007). In 
addition, multiple KCC2 mutations have been associated with epilepsy (Duy et al., 2019).  
In high [Cl−]i conditions (e.g. during development or seizure), opening of GABAA receptor 
channels may result in efflux of Cl− and thus depolarization (Ben-Ari, 2002; Isomura et al., 
2003; Lillis et al., 2012). A recent study has shown that in such conditions, spontaneous 
(action potential-independent) release of GABA, i.e. mIPSCs, contribute significantly to 
recovering low [Cl−]i, similar in magnitude of the activities of KCC2 (Yelhekar et al., 
2017). Furthermore, the study also found that allopregnanolone, an inhibitory neurosteroid, 
hastened the recovery of [Cl−]i. In this thesis, we have demonstrated that kinase activation 
and kindling reduce/abolish potentiation of GABAergic inhibition by THDOC. We 
speculate that decreased neurosteroid efficacy in epilepsy not only affect direct inhibition 
by GABAergic current but may also slow the recovery of low [Cl−]i and contribute to 
chloride imbalance. Such disturbance to chloride homeostasis would further contribute to 
worsening of seizures, as would be the case for epilepsy.  
 Conclusion 
This thesis investigated the effects of phosphorylation on neurosteroid-induced modulation 
of GABAergic inhibition, and how these effects change after kindling. We found that the 
activity of excitatory neurosteroid PregS is not modulated by kinase activation, and PregS 
has no effect on tonic currents of GABAA receptors. However, we found the activity of 
inhibitory neurosteroid THDOC is suppressed by kinase activation. At circuit level, we 
found that THDOC suppressed the activity of PCtx in naïve rats. Kinase activation (PKC, 
PKA, and TrkB) resulted in suppression/abolishment of THDOC effect. In kindled brain, 
we found that THDOC loses its efficacy and PKC activation partially restores its effect. 
Our findings show that protein kinase activities have profound effect on regulating 
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neurosteroid-mediated modulation of GABAergic inhibition and that regulation of kinase 
activity may be able to restore normal neurosteroid functioning in epilepsy.  
 Future directions 
Investigating the effects of PKA and TrkB activators and how they modulate effects of 
neurosteroids in kindled brain would provide further information on how kindling changes 
the PCtx circuit, as we have only looked at PKC activation in kindling. While our 
investigations showed the effects of THDOC and kinases in PCtx circuit, the exact 
mechanisms behind how kinases alter the effect of THDOC remain to be elucidated. To 
address this, we propose studying the effects of protein kinases and THDOC activities in 
layer III and DEn at cellular level via patch clamp. This will provide further information 
on how PCtx circuit activity is regulated by neurosteroids and kinases.  
Furthermore, it remains unclear whether the effect of THDOC on PCtx circuit is solely as 
a result of dampening of layer II (via enhanced tonic inhibition) or the other two layers 
play additional roles. To investigate this, we suggest severing the connection between layer 
II and layer III via mechanically cutting the slice. This will isolate layer II from the other 
layers and will allow for examination of layer II activity and its response to THDOC 
independent of the other layers involved in the circuit.   
This thesis focused only on the postsynaptic effects of protein kinase activation. However, 
previous studies have shown that protein kinases have profound effects on intracellular 
Ca2+ levels, vesicle release mechanisms and probability of vesicle release (Bartmann et al., 
1989; Kondo & Marty, 1997; Majewski & Iannazzo, 1998; Mathew & Hablitz, 2008). For 
example, studies showed that PKC and PKA activation by pharmacological activators and 
GPCRs have been shown to increase IPSC frequencies (Bartmann et al., 1989; Kondo & 
Marty, 1997; Chu & Hablitz, 1998). If mIPSC frequencies in PCtx are increased by these 
kinase activations, small changes to mIPSC kinetics may have large impact on neuronal 
excitability due to much higher frequencies. Our patch clamp experiments (Chapter 2 & 3) 
precluded studying the presynaptic effects of the kinases as we had to apply the kinase 
activators intracellularly due to large increase in mIPSC frequencies (see 2.2.2). For the 
VSDI experiments, we are not able study changes in specific pre- and post-synaptic 
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mechanisms, so it remains unclear whether the changes of THDOC activities by protein 
kinase activations are due to postsynaptic changes to mIPSC kinetics (e.g. 
desensitization/deactivation) or due to some presynaptic mechanism. More detailed patch 
clamp studies of each layer of PCtx circuit are warranted to investigate what pre- and post-
synaptic mechanisms are involved in changes by the pharmacological treatments and 
kindling.  
While VSDI technique is useful in visualizing circuit activities, it cannot provide 
information on cellular activities, such as firing patterns. Previous studies showed that 
firing patterns of the layer III interneurons change after kindling, as they become less 
diverse and favour lower frequency firing (Gavrilovici et al., 2006, 2012). Since the layer 
III interneurons innervate layer II pyramidal cells, there may be similar changes to firing 
patterns of the pyramidal cells. Furthermore, changes to GABAA receptor modulation (e.g. 
by protein kinases and neurosteroids) can alter oscillation of brain circuits (Traub et al., 
1996; Mann & Mody, 2009). Investigating how firing patterns of layer II pyramidal cells 
change in response to protein kinases, neurosteroid and after kindling will provide greater 
insight into functioning of PCtx circuit and mechanisms behind changes seen after 
kindling.  
It would be also of great interest to investigate whether traumatic brain injury (TBI) shows 
similar changes to the effects of neurosteroid and protein kinases seen in kindling. 
Individuals with TBI have higher risk of developing epilepsy, and previous studies have 
shown that TBI can result in changes to PCtx similar to that seen in kindling (Annegers et 
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